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ABSTRACT
This invention relates to methods for forming multi-lamellar microcapsules of both hydrophilic
and hydrophobic immiscible liquid phases using several polymer/solvent systems. Liquid-Liquid diffusion
and spontaneous emulsification are controlled by properly timed sequence exposures of immiscible phases
in aqueous vehicles dispersed in hydrocarbon solvents containing small quantities of oil, co-surfactants,
and glycerides. Water-in-oil and oil-in-water microcapsules are formed containing selected combinations
of several types of drugs, co-encapsulated within fluid compartments inside the microcapsule.
Commercial applications of the process and the resultant product relate to drug therapy for
treating medical conditions such as cancer, circulatory conditions, and other conditions in which
pharmaceuticals are advantageously targeted to specific organs, or delivered in combination with other
pharmaceuticals. Small microcapsules may be delivered intravenously to diseased organs or clotted
vessels. The use of multiple drugs within the same microcapsule structure provides advantages for
applications such as chemoembolization treatments and may be used to deliver both chemotherapeutic
drugs, against tumor cells, and an immuno-adjuvant or immunological stimulant to enhance the patient's
immune response. Active forms of urokinase and other enzymes may be delivered without dilution to the
local site of an embolism for dissolving the embolism. Thus, the invention has several potentially valuable
commercial applications related to pharmaceutical and medical applications.
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MICROCAPSULES AND METHODS FOR MAKING
BACKGROUND OF THE INVENTION
QRIgIN QF THE INVENTIQH
The invention described herein may be manufactured and
used by or for the Government of the United States of
_merica for governmental purposes without the payment of any
royalties thereon or therefor.
A.Fi@Id of the Invention
The invention relates to methods for making
microcapsules, encapsulating pharmaceutical compounds in
microcapsules, microcapsules, microcapsule encapsulated
pharmaceutical compositions and products, and methods of
using the same.
B.D_criDtion of the Related Art
15 Many cytotoxic or bioactive drugs and enzymes cannot be
injected intravenously. Others can be injected, but are
rapidly degraded before they reach the target tissue. Still
others are cleared from the blood by the liver or kidneys so
quickly that their biological half-life is too short to be
20 of therapeutic value. Still other drugs are insoluble in
aqueous solutions. Since intravenous injection in
hydrocarbon solvents is not well tolerated by patients, such
drugs are difficult to administer.
One method for overcoming these limitations is
25 encapsulation into microcapsules or liposomes.
Encapsulation of drugs or biological therapeutics into
!iposomes or liquid microcapsules can enable delivery to
target organs where the bioactive drug can be released
directly by diffusion. Properly designed microcapsules can
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provide unique methods of direct delivery by parenteral
injection, nasal inhalation and dermal administration for
sustained release of important bioactive drugs.
The size and shape of the microcapsules is critical for
5 the distribution and drug delivery in the tissues.
Typically, microcapsules of 1-20 micron diameter are optimum
for intravenous administration, whereas, 50-300 micron
diameter microcapsules are used for intraarterial delivery
and 300 micron or greater for intraperitoneal
I0 administration. In each size range, highly uniform
microspheres are needed for maximum packing densities and
maximum drug payload delivery to target organs or tumors.
Major difficulties with commercial preparation of
microspheres arise when density-driven phase separation of
15 _he immiscible carrier fluids occurs. This is especially
true when the microcapsules are constructed by forming
water/oil emulsions or when attempts are made to encapsulate
multiple drugs. This limits the yield and often results in
microparticles that are not spherical nor uniform in size.
20 Non-conformity limits the packing density (and, thereby, the
drug payload delivered) when the microcapsules arrive at the
target tissues.
Certain current methods of forming microcapsules (such
as liposomes) are based on chemical characteristics of
25 certain phospholipids that self-assemble into bilayers when
dispersed in an excess of water. Most liposomes carry
pharmaceuticals dissolved in the entrapped water phase.
Drugs that are insoluble or that have only limited
solubility in aqueous solvents pose problems for
30 incorporating into liposomes. Such organic-soluble drugs
are usually limited in liposomal formulations to those that
bind inside the hydrophobic region of the liposome bilayer.
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Some drugs are so insoluble that they do not associate with
the bilayer and, therefore, have very low encapsulation
efficiencies. Certain liposomal drug formulations,
including anti-tumor liposomes containing dexorubicin
5 [Gabizion et al. 1992] or muramyltripeptide have been
studied extensively in clinical trials.
Microcapsule formation by liquid-liquid dispersion of
aqueous drugs and organic solvents typically produces
water-in-oil (W/0) type liposomes. A second requisite step
i0 is removal of the organic solvent (typically evaporated) to
form reverse-phase evaporation vesicles (rev) or stable
plurilamellar vesicles (splv).
Spherical multilamellar vesicles (mlv) are rarely
formed by these methods and the size distribution is quite
15 heterogeneous. Typically, in order to generate
multilamellar vesicles, film casting with organic solvents,
hydration and sizing using filtration through inert membrane
filters is required [Talsma and Crommelin 1992]. Methods of
forming multi-layered microcapsules often require
20 emulsification of the aqueous phase into organic carrier
solutions by shear, bubbling or sonication. Sophisticated,
multi-step emulsion technology is required and yields of
uniform type and size are often very low.
Liquid microemulsions also have been developed as drug
25 delivery systems, especially for drugs that are poorly
soluble in aqueous carriers. A microemulsion typically
contains droplets in the range of 0.i - 1 Z in diameter.
Such microemulsions are characterized by very fluid and
dynamic micelles which are formed by sequential mixing one
30 immiscible phase with another using surfactants and
co-surfactants [Bhargava et al. 1987]. Typically,
surfactants that produce water-in-oil (W/O) microemulsions
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have a hydrophilic-lipophilic balance (HLB) rating of 3 to
6, while those that produce oil-in-water (O/W)
microemulsions have an HLB of 8 to 18. The surfactants can
be non-ionic, ionic, or amphoteric. Often, medium chain-
5 length alcohols are added as the co-surfactant in the last
step in achieving the final microemulsion.
The major disadvantages of microemulsions is that each
micelle (liquid capsule) is too small (typically, less than
1.0 micron) for deposition in larger vascular beds when
i0 administered by intravascular injection. Therefore,
microemulsions are not suitable for chemoembolization type
treatment of vascularized tumors. Additionally, since
microemulsions are true colloidal suspensions, they cannot
be scaled up to large enough size for many intravascular
15 drug delivery applications. Microemulsions formed with lipid
soluble anti-tumor agents and low density lipoproteins
(LDLS) have been used to target drugs to neoplastic cells
that require large amounts of cholesterol for synthesis of
cell membranes [Halbert et al. 1984]. However, LDLs also
20 attract phagocytes making the amount of drug actually
delivered to the tumors and thence the therapeutic dose
difficult to determine.
The use of solid matrix microspheres containing
adsorbed drugs within the matrix is also known. For
25 instance, U.S. Patent 4,492,720 to Hosier disclosed methods
for making microspheres to deliver chemotherapeutic drugs
(including Cis-Platinum) to vascularized tumors. This
method of preparing microspheres is accomplished by liquid
encapsulation and solid-phase entrapment wherein the
30 water-soluble drug is dispersed in a solid matrix material.
The method involves dissolving the aqueous drug and the
matrix material in a organic solvent, in which they are
-4-
MSC-22489-I
Express Mail Certificate #GB039540919US
Patent Application
mutually soluble, then dispersing this mixture in a second
organic solvent to form an emulsion that is stable enough
for intravascular injection.
Other approaches have utilized copolymers such as
5 polyvinyl chloride/acrylonitrile dissolved initially in
organic solvents to form microparticles containing, for
instance aqueous enzyme solutions. U.S. Patent No.
3,639,306 to Sternberg et al. discloses a method of making
anisotropic polymer particles having a sponge-like inner
i0 support structure comprising large and small void spaces and
an outer, microporous polymer film barrier. A multiple-step
batch process is used which entails removal of the organic
solvents used to dissolve the polymers prior to addition of
aqueous components. Solid-matrix microspheres, however, are
15 often not perfect spheres thereby limiting the packing
density. Additionally, many drugs cannot be trapped or
adsorbed in these systems at effective concentrations and
drug-release rates are often not constant.
Conventional methods of forming of multi-lamellar,
20 immiscible, liquid microcapsules are limited, because of
density-driven phase separation and stratification into
horizontal layers resulting in the necessity to use
multi-step, batch processing including mechanical mixing and
solvent evaporation phases [Talsma and Crommelin 1992]. Each
25 batch step suffers losses which reduce overall efficiencies.
Conventional methods do not permit simultaneous formation of
the outer skin as the microcapsule itself is formed. Many
conventional therapeutic microspheres have natural
phospholipid outer skins (usually in combination with
30 cholesterol and a fatty amine) and therefore are subject to
elimination by immune cells. Other conventional methods use
sialic acid and other coatings on the lipid bilayer to mask
5
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the liposomes from detection by the scavenging systems of
the body. Without an adequate outer skin, microcapsules
often coalesce thereby reducing shelf-life.
For instance, U.S. Patent No. 4,855,090 to Wallach,
5 discloses a method of making a multilamellar lipid vesicle
by blending an aqueous phase and a nonaqueous lipophilic
phase using a high shear producing apparatus. The
lipophilic phase is maintained at a high temperature (above
the melting point of the lipid components) and is combined
i0 with an excess of the aqueous phase, which is also
maintained at a high temperature. U.S. Patent No. 5,032,457
to Wallach discloses a paucilamellar lipid vesicle and
method of making paucilamellar lipid vesicles (PLV). The
method comprises combining a nonaqueous lipophilic phase
15 with an aqueous phase at high temperatures and high shear
mixing conditions, wherein the PLVs are rapidly formed in a
single step process.
U.S. Pat. No. 4,501,728 to Geho et al. discloses the
encapsulation of one or more drugs or other substances
20 within a liposome covered with a sialic acid residue for
masking the surface of the membrane from scavenging cells of
the body utilizing techniques known for the production of
liposomes. In one embodiment, additional tissue specific
constituents are added to the surface of the liposome which
25 cause the liposome thusly treated to be attracted to
specific tissues. Similarly, U.S. Patent 5,013,556 to
Woodle et al. provided methods for making liposomes with
enhanced circulation times. Liposomes created by this
method contain 1-20 mole% of an amphipathic lipid
30 derivatized with a polyalkylether (such as phosphatidyl
ethanolamine derivitized with polyethyleneglycol). U.S.
Pat. No. 5,225,212 to Martin et al. discloses a liposome
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composition for extended release of a therapeutic compound
into the bloodstream, the liposomes being composed of
vesicle-forming lipids derivatized with a hydrophilic
polymer, wherein the liposome composition is used for
5 extending the period of release of a therapeutic compound
such as a polypeptide, injected within the body.
Formulations of "stealth" liposomes have been made with
lipids that are less detectable by immune cells in an
attempt to avoid phagocytosis [Allen et al. 1992]. Still
i0 other modifications of lipids (i.e., neutral glycolipids)
may be affected in order to produce anti-viral formulations.
U.S. Patent 5,192,551 to Willoughby et al. 1993. However,
new types of liposomes and microcapsules are needed to
exploit the various unique applications of this type of drug
15 delivery.
It is known that microgravity can be advantageously
utilized to induce and maintain crystal growth due to the
lack of density driven convective flow in liquids. U.S.
Patent No. 4,909,933 to Carter et al. discloses an apparatus
20 for carrying out crystallization of proteins and chemical
syntheses by liquid-liquid diffusion in microgravity
environments. The apparatus comprises a housing having a
plurality of chambers and a valve which separates at least
two of the chambers so as to allow controlled fluid flow.
25 The disadvantages of conventional liposomes or
microcapsules include manufacturing methods that require
many batch process steps to: i) form the liposomes, 2)
remove unwanted organic solvents, detergents, and 3) harvest
the proper size and shape microparticles for optimum
30 pharmacologic efficacy [Talsma and Crommelin 1992]. Also
conventional liposomes often use natural lipids and lectins
(from eggs, soybeans and other inexpensive sources) which
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attract phagocytic immune cells that rapidly remove the
liposomes from the circulatory system before they arrive at
the target tissue. This creates variable dose-responses
making calculations of pharmacokinetics and therapeutic
5 doses very difficult [Allen 1988]. Major difficulties with
commercial preparation of microcapsules often involves
density-driven phase separation of the immiscible carrier
fluids, esp. when forming water/oil systems.
These drawbacks limit the yield, make it difficult to
i0 harvest the proper size particle, and often result in micro-
particles that are not spherical nor uniform in size,
thereby limiting the packing density (and drug payload
delivered) when the microcapsules arrive at the arterioles
or capillaries in the target issues. Liposomes have a
15 bilayer outer membrane which requires that the entrapped
drug must be soluble in both the aqueous and lipid phases in
order to outwardly diffuse. This limits the type of drugs
that can be released from conventional liposomes and the
mole ratio of aqueous to lipid phases limits the amount of
20 drug which can be delivered.
Processes are needed for forming spherical multi-
lamellar microcapsules having alternating hydrophilic and
hydrophobic liquid layers, surrounded by flexible,
semi-permeable hydrophobic or hydrophilic outer membranes
25 which can be tailored specifically to control the diffusion
rate. In particular, methods of making such microcapsules
are needed which do not rely on batch processes involving
density-driven phase separation and stratification into
horizontal layers, mechanical mixing and solvent evaporation
30 phases. Moreover, there is clearly a need for methods and
compositions which allow for uniform size and more spherical
microcapsules. Such improved microcapsules would be
8
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particularly useful in the delivery of pharmaceutical
compositions.
SUMMARY OF THE INVENTXON
Processes and compositions are providedby the present
5 invention which overcome certain of the limitations of prior
methodology for forming microcapsules. In particular,
methods and compositions are provided which form multi-
lamellar microcapsules having alternating hydrophilic and
hydrophobic liquid layers, surrounded by flexible,
i0 semi-permeable hydrophobic, outer membranes which can be
tailored specifically to control the diffusion rate. In
particular, the methods of making microcapsules provided by
the present invention do not rely on batch processes such as
density-driven phase separation and stratification into
15 horizontal layers, mechanical mixing or solvent evaporation.
Encapsulation of cytotoxic or labile drugs in such
microcapsules enables targeted delivery and sustained
release kinetics that are not currently available with
intravenous injection.
20 The invention provides, in one aspect, methods of
making a multi-layered microcapsule. The term microsphere
as used herein is a general term which can include any
spherical microscopic vesicle including microspheres,
micelles, inverted micelles, bilayer vesicles and liposomes.
25 The term microcapsule as used herein is a more specific term
which refers to a microsphere which comprises at least two
layers, one of which is innermost and is substantially
completely enclosed within the other. In a distinct break
from traditional methods for making microcapsules, the
30 methods of the invention rely on low shear mixing and
liquid-liquid diffusion process, particularly as developed
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for forming microcapsules that may contain both aqueous and
hydrocarbon soluble drugs.
The terms multi-layered and multi-lamellar are used
interchangeably throughout the specification and claims and
5 both refer to the fact that the microcapsules of the
invention comprise at least two immiscible layers nested
around one another. In some instances, the core layer will
be hydrophobic in nature and will be completely surrounded
by at least one neighboring hydrophilic layer. In others,
i0 the core layer will be hydrophilic in nature and will be
completely surrounded by at least one neighboring
hydrophobic layer.
The basic method of the invention relies on liquid-
liquid interactions. In the basic method, the first step
15 entails formulating a first phase or layer while the second
step entails formulating a second phase or layer. The two
phases or layers are formulated to be immiscible with one
another. For the purposes of this invention, "immiscible"
means that the solubility of one phase or layer is not more
20 than 10gm/100ml in an adjoining phase or layer and that the
two adjoining phases or layers form an interface resembling
a meniscus.
Formulating the first phases or layer comprises
combining a first solvent, a first polymer soluble in the
25 first phase, a co-solvent, an oil, and water. The first
solvent will typically comprise about 75-90% by volume of
the first phase. The first polymer is selected to be one
soluble in the first phase and typically will comprise about
1-5% by volume of the first phase. A small amount of a co-
30 solvent is also added to the first phase, which co-solvent
may also function as a co-surfactant. Oil comprising about
-i0-
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1-10% by volume is also added to the formulation. The first
phase will also contain about 1-5% water by volume.
The method next calls for formulating a second phase
immiscible with the first phase. The second phase comprises
5 a second solvent, a second polymer soluble in the second
phase, a surface active agent, and a salt. The relative,
approximate volume percentages of these constituents is
about 70-98% second solvent, 1-10% second polymer, 1-4%
surface active agent, and 1-3% salt.
i0 In order to ensure that the liquid-liquid interactions
necessary to form the microcapsule will occur, certain of
the constituents of each phase are selected relative to one
another. Thus, the surface active agent in the second phase
is selected such that it will have a hydrophilic/lipophilic
15 balance value greater than that of the first polymer
constituent of the first phase. Generally, the most useful
surface active agents have been found to be those which are
nonionic and which have a hydrophilic/lipophilic balance
value of i0.0 or greater. Next, the second polymer
20 constituent of the second phase is selected to have a
hydrophilic/lipophilic balance value lower than that of the
surface active agent constituent of the same phase. While
not an exhaustive list, certain hydrophilic/lipophilic
balance values of materials which may be used in the
25 formulations of the invention are provided below.
30
HYDROPHILIC/LIPOPHILIC BALANCE (HLB)
ComPound
Glycerol treideate
Cholesterol
Triglyceride of coconut oil
Sorbitan tiroleate
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HLB
0.8
1.0
1.4
1.8
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5
i0
15
2O
25
Compound
Sorbitan tristearate
Glycerol monooleate
Mono and di glycerides of fat burning
fatty acids
Glycerol Monostearate (gms)
Propoxylated ethylene diamine plus
ethylene oxide
Mono/diglyceride
Glycerol mono coconut
Mono/diglyceride
Propylene glycol mono fatty acid ester
Monoethoxyl lauryl ether
Stearyl lactyl acid
Hydrogenated cottonseed oil
Sodium lauryl sulfate
Mono and diglycerides with citric acid
or
lactylic ester or fatty acid
Ethoxylated fatty amine (2 moles ETO)
Diethylene glycol monostearate
Sorbitan monopalmitate
Diethylene glycol monostearate and
oleate
Ethoxylated (2) cetyl ether
Glycerol Monoricinoleate
Glycerol monolaurate
Triglycerol mono stearate
Polyethylene glycol (400 dioleate)
Lanolin sterol
HLB
2.1
2.7
2.8
2.8-5.0 (3.8
preferred)
3 - 28
3.2
3.4
3.5
3.5
3.6
3.8
3.8
4.0
4.2-4.6
4.5
4.7
4.7
4.7
5.3
6.4
6.8
7.0
7.2
8.0
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5
i0
15
2O
25
3O
CQmDound
J
Ethoxylated nonyl phenol (C0-420 & CO
85O)
Polyethylene glycol (400) distearate 8.2
Sorbitan monolaurate 8.6
Ethoxylated sorbitan fatty acid esters 9.0
and alkyl/aryl alcohol
Anhydrous lanolin i0.0
Polyethylene glycol monostearate 11.0
Polyethylene glycol 400 11.2
Ethoxylated (i0) cetyl ether 12.9
Ethoxylated glycerol monostearate (gms) 13.1
Sorbitan monostearate 14.9
Sorbitan monooleate with 20 moles 15.0
ethylene oxide
Ethoxylated (20) oleyl ether 15.3
Ethoxylated (20) stearyl cetyl ether 15.8
Ethoxylated castor oil 18.0
Nonyl phenol polyethylene glycol ether 18.1
Polyethylene glycol 600 mono laurate 19.6
Sodium lauryl sulfate 40
Propylene glycol monostearate 40
Hydroxylated lanolin sodium oleyl 42
sulfate
Blends of GMS and sorbitan monooleate 52
with 20 mols ethylene oxide
HLB
8.0-16.0
The basic method next involves creating an interface
between the first and second phases. The creation of the
interface is achieved in such a way that minimal shear and
mixing occurs between the phases. The two immiscible phases
are brought together in such a mechanical manner that the
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fluid shear properties are controlled to low levels, below
about 12 dynes/cm2] and such that the adsorptive surface
properties at the immiscible interfaces are not
significantly altered. Although the exact mechanisms are
5 not fully understood, the inventors believe that the
maintenance of certain surface properties, such as the
surface tension, Helmholtz charge distribution (electrical
double layer), and partitioning of the surfactant molecules
between the immiscible phases must remain substantially
I0 intact so that lateral phase separation can occur in a
manner which allows simultaneous formation of multiple
liquid interfaces (oil/water or water/oil) and which results
in microcapsules having alternating spherical shells of
hydrophilic and hydrophobic liquid layers. This is believed
15 to be the mechanism for the formation of multi-lamellar
vesicles which are formed in a single step. Although this
can best be demonstrated under microgravity conditions,
wherein buoyant convection is absent and diffusion-driven
convection predominates, this also can be accomplished in
20 unit gravity conditions by balancing the density differences
between the two liquid phases or by any other mechanical
means which prevents excess fluid shear from significantly
altering the normal adsorptive surface properties which are
determined by the chemical composition of the formulas and
25 the interfacial phenomena among the solvents, polymers and
surfactants. In a preferred embodiment, the creation of the
interface will occur by sliding individually separated
compartments containing the two phases into register with
one another in a manner that substantially limits shear and
30 provides gentle mixing.
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In the final step of the basic method, conditions are
established in order to substantially limit all mixing
between the interfaced liquid phases. In the most preferred
environment, the two phases would be allowed to interact at
5 their interface without agitation, stirring, shearing or
like force. It is preferred to also limit even those
quiescent forces such a gravity-controlled sedimenting,
shifting, drift and the like. Thus, in certain preferred
embodiments, only chiefly diffusion-driven convection is
i0 used to spontaneously form microcapsules, as the chemical
formulations of the different phases assist in lowering the
surface free energy across the interface. It is also at
this time that formation of the polymeric outer coating is
initiated.
15 In one embodiment, the two liquids thus formulated are
separated into distinct compartments or spaces which spaces
are each connected to a central diffusion chamber into which
each compartment can deliver its resident liquid loading.
The compartments are initially closed to access into the
20 central diffusion chamber so that the first and second
liquids are kept apart from one another and not allowed to
interact. While it is possible to use any number of devices
to achieve this separation, a preferred device is a device
like the Materials Dispersion Apparatus described in more
25 detail below. The separation of the two liquids is
maintained until both liquids and the device containing them
can be placed in an environment in which convective mixing
may be minimized, such as in a microgravity environment.
The methods of the invention are slightly different
30 depending upon whether the first solvent is selected to be
organic or aqueous. Where an organic solvent is used to
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formulate the first phase, that organic solvent is selected
from the group of'organic solvents consisting of ethyl
alcohol, methyl alcohol and isopropyl alcohol. Where an
organic first solvent is used to formulate the first phase,
5 the first polymer is selected to be one soluble in the
organic solvent selected. Such a first polymer may be
selected from the group of polymers consisting of glycerol
monosterate, glycerol monooleate, glycerol monolaurate,
glycerol dioleate, glycerol disterate, cholesterol,
i0 stigmasterol, phytosterol, campesterol, and lecithins such
as phosphatidyl cholines (e.g., Centrolex-F').
Where the first solvent is aqueous, a slightly
different approach is taken. In those instances, the first
polymer is again requisitely soluble in the first aqueous
15 phase and may be selected from the group of polymers
consisting of polyvinyl pyrrolidone, polyvinyl alcohols,
gelatin, gum tragacanth, carrageenan, Karaya gum, Guar gum,
gum arabic, alginates, carboxymethyl cellulose,
hydroxypropyl cellulose, carboxypropyl cellulose, and
20 lecithins.
Regardless of the formulation with an aqueous or
organic first solvent and polymer, the methods of the
invention both use a co-solvent which may be selected from
the group of co-solvents consisting of C3-Cs alcohols,
25 tetrahydrofuran, dioxane, acetonitrile, dimethylformamide,
dimethylacetamide, and dimethyl sulfoxide. Similarly
regardless of the organic/aqueous nature of the first
solvent and polymer used, the methods of the invention add
to the formulation of the first phase an oil. These oils
30 may be selected from the group of oils consisting of
unsaturated oils such as poppy seed oil, olive oil, peanut
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oil, sesame oil, cotton seed oil, soybean oil, safflower
oil, corn oil, suHflower seed oil and canola oil or
saturated oils such as mineral oil, long chain paraffinic
oil, and liquid petrolatum. In a preferred embodiment,
5 poppy seed oil will be iodinated to form iodinated poppy
seed oil (IpO) and incorporated into a microcapsule as a
marker or tracer for tracking the presence of the
microcapsule once injected via radiocontrast detection
methods known well to those of skill in the art of
i0 radiography.
Whether the method involves an organic or an aqueous
first solvent, the second polymer, the surface active agent
and the salt may each be selected from a particular group of
such compounds. The second polymer may be selected from the
15 group of polymers consisting of polyethyleneglycol 1000-8000
daltons, dextran i000-i0000 daltons, polyvinylpyrrolidone,
polyvinyl alcohols, gelatin, gum tragacanth, carrageenan,
Karaya gum, Guar gum, gum arabic, alginates, carboxymethyl
cellulose, hydroxypropyl cellulose, carboxypropyl cellulose,
20 and lecithins. The surface active agent is selected from
the group of surface active agents consisting of sorbitan
monooleate treated with ethylene oxide, dextran,
polyethylene glycol, C12-C_0 fatty acids, 2-amino-2-methyl-l-
propyl aminomethyl propanol amphoteric salts and quaternary
25 ammonium salts. The salt is selected from the group of
salts consisting of NaCI, KCI, CaCI 2, MgCI 2, quaternary
ammonium salts, cetyl trimethylammonium bromide and 4-
methoxy-4(3-phosphatidyl choline)spiro(l,2-dioxetane-3-g,l-
adamantane) disodium salt.
30 In certain embodiments of the methods of the invention,
pharmaceutical compositions will be incorporated into the
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microcapsule. Where such pharmaceuticals are thusly
incorporated, they may be introduced initially as a solute
or as particulates suspended in one or the other of the
liquids used to formulate the layers of the microcapsules.
5 In certain embodiments, the pharmaceutical is introduced in
one of the phases or layers used to produce the microcapsule
at a concentration sufficient to allow nascent crystal
formation within said microcapsule. Crystal formation may
occur at or near the time of formation of the microcapsule
i0 containing the dissolved pharmaceutical material. The
aqueous solvent system used to dissolve an aqueous-soluble
pharmaceutical is selected to permit water molecules to
migrate away from the drug-containing layer into the
alcoholic mixture. The process of crystal formation is
15 likely to be promoted in this manner after formation of the
microcapsule. In fact, it is possible to enhance the
crystallization process after the microcapsule is formed by
controlled transport of the solvent phase or layer in which
the pharmaceutical to be crystallized is a solute. It
20 certain embodiments, the crystal thus formed may take up
most of the internal capacity of the microcapsule.
Multi-layered microcapsules, with both hydrophobic and
hydrophilic drug compartments, as produced by the methods of
the invention enable diffusion of complimentary drugs from
25 the same microcapsule, e.g. antibiotics and
immuno-stimulants to treat resistant infections or multiple
fibrinolytic drugs to dissolve emboli. Co-encapsulation of
radio-contrast medium as provided herein enables oncologists
to monitor the delivery of anti-tumor microcapsules to
30 target tumors using computerized tomography and radiography
that track the distribution of microcapsules after release
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from the intra-arterial catheter. Such microcapsules will
have important applications in chemotherapy of certain
liver, kidney, brain and other tumors.
The diameters of microcapsules possible to attain using
5 the methods of the invention are also of particular
usefulness in medical applications. Thus, whereas prior art
methods have been able to routinely produce microspheres
over i-i0 micron average sizes, the present invention's
methods provide similarly-sized microcapsules of 1-20 micron
I0 diameters for intravenous administration. Also provided are
50-300 micron sized microcapsules particularly useful in
interarterial chemoembolization of tumors, and microcapsules
in the range of 300 micron and greater diameters useful in
interperitoneal administered drugs.
15 The pharmaceutical composition encapsulated in the
microcapsule may be one soluble in aqueous solutions or may
be one soluble in organic solutions. This, of course,
governs the selection of the phase or layer in which the
pharmaceutical composition is formulated. The microcapsules
20 of the invention and methods for producing them are of
particular utility when formulating organic-soluble drugs as
these type of drugs are otherwise very difficult to
administer. The pharmaceuticals may be those selected from
the group of such widely diversified pharmaceutical
25 compositions as that consisting of cytoxins, proteases,
cytokines, anti-nauseants, steroids, anti-fungal agents,
fibrinolytic enzymes, and antibiotics. The inventors have
successfully encapsulated representatives of these classes
of pharmaceuticals using the methods of the invention. It
30 is also possible to incorporate a pharmaceutical composition
which is not initially dissolved in one or another of the
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phases or layers, but rather which drug is in suspension.
As noted above, depending upon its solubility and upon where
the pharmaceutical chemist wishes to locate the drug, it is
possible to formulate a drug in any of the phases or layers,
5 by dissolving or suspending the drug as needed.
The methods of the invention surprisingly demonstrated
the ability to package very high concentrations of drugs in
the layers formed. It is possible, using the methods of the
invention, to formulate a pharmaceutical at a concentration
i0 sufficient to allow nascent crystal formation within the
microcapsule once it is formed. These microcapsules, due in
one regard to their being constructed with outer polymeric
coatings, are also particularly flexible yet rugged (able to
withstand shear forces greater than I0 dynes/cm2). As will
15 be related specifically below, microgravity experiments, on
sounding rockets (1989-92) and Shuttle missions STS-52
(1992) and STS-56 (1993) using an automated Materials
Dispersion Apparatus, produced multi-lamellar microcapsules
containing both Cis-platinum (anti-tumor drug) and iodinated
20 poppy seed oil (a non-radioactive, radiocontrast medium),
surrounded by a polymeric skin. Microcapsules formed with
amoxicillin (antibiotic) or urokinase (a clot dissolving
enzyme), co-encapsulated with IPO, were still intact after
two years after return to 1 x g environments. In many
25 instances, microcapsules were formed with the Cis-Platinum
or amoxicillin so concentrated that crystals of the drugs
formed inside.
Surprisingly, the methods of the invention have
demonstrated a unique ability to encapsulate such saturated
30 drug solutions, and since the overall partitioning
characteristics between immiscible layers facilitates
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solvent transport out of the aqueous layer, it is possible
to concentrate the drug to the point that formation of drug
crystals occurs within the microcapsules. This ability of
the microcapsules and methods of the invention provides the
5 maximum drug payload per microcapsule and the best drug
release kinetics for prolonged treatment at maximum drug
diffusion rates.
Microcapsules containing a large volume component of
crystalline drug provide the most concentrated drug possible
i0 when it is released at the target site. Until the crystals
are completely dissolved, the drug release rate is
independent of time (zero order release kinetics). When the
crystals have dissolved, the drug release rates revert to
first order kinetics (exponential with time). The
15 encapsulated crystals of the invention are in the range of
1-50 microns in diameter. Since these crystals are
precipitated in situ, they are quite different from the
other commercially-available crystalline drug delivery
systems (e.g., Microcrystal') which use phospholipids to
20 encapsulate tiny particles or crystals of drugs with an
average diameter of only 0.3 - 1.0 micron [Parikl and Stern
1994].
It is also possible to additionally treat the
microcapsules thus formed with additional steps. In some
25 instances, the methods of the invention, regardless of
whether they initially use an organic or an aqueous first
solvent, formulate a third phase comprising an oil or C20-C38
paraffin and, contact the formed microcapsule with the third
phase. In other instances, the methods of the invention
30 form a two-layered microcapsule, then formulate a third
phase comprising an aqueous solution and, contact the formed
-21-
MSC-22489-I
Express Mail Certificate #GB039540919US
Patent Application
microcapsule with the third phase.
alternatives are s_marized below.
The basic method and
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Solution 1
Solution 2
Solution 3
Group 1
Solvent 1 is a hydrocarbon
Polymers are hydrocarbon soluble,
selected to form the outer coating
(typically of lower HLB values)
Co-solvents alcohols, hydrocarbons (act
as co-surfactants)
Oils saturated or unsaturated oils
dissolved (or suspended
particulate)
Solvent 2 aqueous
Polymers water soluble (PEG, Dextran)
Surfactants (typically higher HLB
value)
Salts ionic, quaternary ammonium salts
aqueous soluble
Oils hydrocarbons
Polymers hydrocarbon-soluble
Group 2
Solvent 1 is aqueous
Polymers (skin) are water soluble,
but can be extended into organic
phase (includes phospholipids) Ex.
Centrolex F"
Co-solvents same, but often less %
Oils same
dissolved (or particulate)
Solvent 2 same
Polymers same
Surfactants same but often less %
_;alts same, but often different %
aqueous soluble
Oils same
Polymers same
can be included
-- OR --
Alternative aqueous solution
.__0!L0.g-adjuvan ts
immunoglobulins
polymers - aqueous soluble
surfactants -
can be included
-- OR --
Alternative aqueous solution
coating same
polymer same
surfactants same
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Traditional emulsion methods form a O/W/O
(oil/water/oil) of W/O/W (water/oil/water) liquid system
which is designed to retain the internal phase(s) within the
external solvent unless the emulsion is broken, whereupon
5 the liquid phases separate. In the methods Of the
invention, the use of surfactants and co-surfactants permits
formation of an emulsion of large spheroids (not small
microspheroids) of one phase dispersed in the other phase
configured in a sphere. The sphere is also Surrounded by
I0 another immiscible liquid layer (opposite phase to that of
the innermost liquid sphere) and then (often) this multi-
layered sphere is contained in another opposite-phase liquid
layer and finally the entire multi-layered sphere is
contained in an outer skin. The results of the process of
15 the invention are not to form a traditional O/W/O or W/O/W
emulsion (which is a fine dispersion of one phase in
another), but rather to form multi-lamellar, alternating
immiscible-layer microcapsules contained within a thin,
semi-permeable outer skin. In the microcapsules of the
20 invention, the immiscible phases are distinct and separated
according to the surface tension characteristics of the
liquids at each interface, hence there is no true emulsion
maintained by the surfactant which could be broken.
Thus, in certain embodiments of the methods and
25 compositions of the invention, the multi-layered
microcapsule will be produced which comprises at least three
alternating layers or phases. Thus, if the first layer is
an aqueous layer or core, the next layer may be an organic
layer. This organic layer may then be covered over by a
30 second aqueous layer which forms on its outer surface a
polymeric skin. Conversely, the liquid at the core of the
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microcapsule may be an organic liquid layered over by an
aqueous layer followed by another organic layer which forms
a polymeric skin over the surface of the microcapsule.
Certainly, extension of these basic formulations may be
5 envisioned where four or more layers are possible or where
multiple skins or coatings are utilized.
Whether used in conjunction with a two-layer
microcapsule or with microcapsules with more than two
layers, the coatings of the present invention are of
i0 substantial utility, particularly when the methods are
carried out at earth-normal gravity. The coatings can be
either substantially of a hydrophobic nature or of a
hydrophilic nature as described below and are derived from
addition of certain polymers in the initial formulations of
15 the liquids used to make the microcapsules. Where
hydrophobic coatings are used in conjunction with drug-
delivery systems, the coatings are selected for their
complementary permeability to the drug to be delivered. The
polymers are also selected for their flexible
20 characteristics after formation and curing which is of
particular utility during intravascular transport and allows
higher packing densities for forming emboli such as in
chemoembolization therapy. Thus, for example where a water-
soluble drug is to be delivered, the drug is contained in an
25 inner aqueous layer over which is placed a coating permeable
to the dissolved drug. Preferably, the coating material
should be impermeable to solvents or oils. The coatings
which have been observed to be deposited on the surfaces of
the microcapsules of the invention are about 0.01-2.0
30 microns thick where the coating is a hydrophobic coating,
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and about 0.1-5.0 microns thick where hydrophilic coatings
are deposited. '
The additional steps and third formulated phases may
also be used advantageously to provide the microcapsule with
5 specific characteristics. Thus, the third phase may further
comprise a pharmaceutical composition which is added to the
formed surface of the microcapsule. The third phase may
also be used to add a pharmaceutical composition such as an
adjuvant. The adjuvant may further comprise an
i0 immunoglobulin, other protein, hydrocolloid or
polysaccharide. This is of particular utility in designing
microcapsules with unique immunologic, proteinaceous or
other surface characteristics which makes them selectively
adhere to certain target tissues (cells) or renders the
15 microcapsules attractive to certain phagocytic cells (when
the cells are the actual target for the therapeutic drug).
Where the adjuvant is a hydrocolloid, it may be selected
from the group of such hydrocolloids consisting of collagen,
isoelectric gelatin, agar, gum arabic, gum tragacanth,
20 alginates, cellulose derivatives and carrageenans. The
third phase may also further comprise a surface active
agent.
The third aqueous phase can also contain a chemical
activator which acts upon the inactive form of the
25 pharmaceutical agent (drug) as is diffuses out of the inner
layers of the microcapsule. The function of the activator
is to chemically convert the inactive drug to its active
form just before it is released from the microcapsule. This
is illustrated when the pharmaceutical is a pro-enzyme and
30 where the activator is another proteolytic enzyme which
cleaves the pro-enzyme at active site to render the molecule
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biologically active. This embodiment can be used to deliver
very labile drugs Which have very limited shelf-lives or
short biological half-lives whereupon the activator (third
phase) can be added shortly prior to intravascular
5 administration such that the inactive drug becomes activated
after the microcapsules have reached the target site. This
can maximize the therapeutic effectiveness of the short-
lived drug at the target site of action.
One or more of the phases of the microcapsule of the
i0 invention may further comprise fluorescent molecules
selected from the group of fluorescent molecules consisting
of fluoresceins, cyanins, naturally fluorescent molecules,
and rhodamines. This is particularly useful where
radiocontrast media are not desirable or where an additional
15 tracking method is useful or where it is of value to monitor
the presence or absence of a layer in the microcapsule,
fluorescent molecules may be incorporated into the
microcapsule of the invention. Thus, for instance, as
described more fully below, it may be useful to incorporate
20 a hydrophilic fluorescent molecule in the aqueous liquid in
order to determine the relative location and number of
aqueous liquid layers in a certain production batch of
microcapsules produced by the methods of the invention.
Critical to the success of the methods of the invention
25 is the substantial limitation of mixing between said phases
to diffusion-driven convection. One manner in which to so
limit other types of mixing is to carry out the methods
under microgravity. Microgravity is defined as a gravity
force of less than 1 x 10 .3 x g. Such gravitational
30 environments may be achieved in a variety of ways, at least
some of which are detailed herein. For instance,
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microgravity may be achieved in certain trajectories of
sounding rockets.' Even longer periods of microgravity may
be obtained with temporary orbiters such as the space
shuttle. Relatively indefinite periods of microgravity may
5 be obtained in permanent or semipermanent orbital space
craft such as the orbital space station and other
geosynchronous orbital satellites. The exposure of the
first and second liquids to microgravity has been found to
be effective in forming the microcapsules of the invention
I0 where the exposure is at least 6.5 minutes in duration.
Certainly, as described more fully below, greater exposure
periods have also been proven successful. The inventors
anticipate that periods of exposure as short as 1.0 minute
will also produce adequate numbers of microcapsules.
15 In preferred embodiments, however, the methods of the
invention will not use microgravity in order to limit mixing
between the phases. Of course, such limitations of mixing
can be promoted by carrying out the methods below ambient
temperature. Limitation of interactions between the phases
20 is best promoted by substantially balancing the specific
gravity between said phases as is described below. The
formulations and methods necessary to achieve earth-normal
microcapsule formation are described in greater detail
herein. In either case, or in combinations of these
25 techniques, mixing between the two phases may be chiefly the
result of diffusion-driven convection.
The inventors have found that there is a greater size
distribution which results from microencapsulation at earth-
normal gravity. At least a partial reason for this wider
30 size distribution is apparently the inability under earth-
normal gravity to avoid certain sedimentation phenomena
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alone and sedimentation effects combined with weight-related
contact of sedime_ted microcapsules. These facts require
some additional manipulation under earth-normal environments
not required in the 0 x g environments -- namely, sieving of
5 the resulting microcapsules in order to generate more
uniform fractions. Therefore, at earth normal gravity, the
utility of the outer coating of the microcapsules of the
present invention become even more important. Enhancing the
ruggedness of the earth-normal microcapsules by curing and
i0 other steps as related herein may also be used.
A preferred method of making a multi-layered
microcapsule comprises: formulating a first phase comprising
an organic solvent selected from the group of organic
solvents consisting of ethyl alcohol, methyl alcohol and
15 isopropyl alcohol, a first polymer soluble in the first
phase selected from the group of polymers consisting of
glycerol monosterate, glycerol monooleate, glycerol
monolaurate, glycerol dioleate, glycerol disterate,
cholesterol, stigmasterol, phytosterol, campesterol,
20 lecithins such as phosphatidyl cholines (e.g., Centrolex-
F'), a co-solvent selected from the group of co-solvents
consisting of C3-C8 alcohols, tetrahydrofuran, dioxane,
acetonitrile, dimethylformamide, dimethylacetamide, and
dimethyl sulfoxide, an oil selected from the group of oils
25 consisting of poppy seed oil, olive oil, peanut oil, sesame
oil, cotton seed oil, soybean oil, safflower oil, corn oil,
sunflower seed oil, canola oil (unsaturated oils), or
mineral oil, long chain paraffinic oil, and liquid
petrolatum (saturated oils), and water; formulating a second
30 phase immiscible with the first phase, the second phase
comprising water, a second polymer soluble in the second
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phase selected from the group of polymers consisting of
polyethyleneglyco2 1000-8000 daltons, dextran I000-i0000
daltons, polyvinylpyrrolidone, polyvinyl alcohols, gelatin,
gum tragacanth, carrageenan, Karaya gum, Guar gum, gum
5 arabic, alginates, carboxymethyl cellulose, hydroxypropyl
cellulose, carboxypropyl cellulose, lecithins, a surface
active agent selected from the group consisting of sorbitan
monooleate treated with ethylene oxide, dextran,
polyethylene glycol, Cn-C20 fatty acids, quaternary ammonium
i0 salts, and a salt selected from the group of salts
consisting of NaCI, KCI, CaCI2, MgCI2, quaternary ammonium
salts, cetyl trimethylammonium bromide, 2-amino-2-methyl-l-
propyl aminomethyl propanol, and 4-methoxy-4(3-phosphatidyl
choline)spiro(l,2-dioxetane-3-g,l-adamantane) disodium salt;
15 the surface active agent having a hydrophilic/lipophilic
balance value greater than that of the first polymer; the
second polymer having a hydrophilic/lipophilic balance value
lower than that of the surface active agent; creating an
interface between the first and second phases in a manner
20 that substantially limits fluid shear; and, substantially
maintaining adsorptive surface characteristics of said
interface.
Microcapsule products produced by any of the methods of
the invention are also claimed. The methods of the
25 invention are used to form unique multi-lamellar,
microcapsules, having alternating hydrophilic and
hydrophobic liquid layers surrounded by a flexible,
semi-permeable, polymeric outer "skin" The outer skin which
can be either hydrophilic or hydrophobic, is designed to
30 allow controlled drug diffusion out of the microcapsule.
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Unlike any natural phospholipid or other component of
cell membranes, the outer skin of the microcapsules of the
invention avoids recognition and phagocytosis by immune
cells, thereby increasing the amount of drug delivered to
5 the tissues. The multi-layered microcapsules of the
invention can entrap multiple drugs in different solvent
compartments and saturated solutions of drugs which may then
form crystals inside the microcapsule. Radiocontrast medium
can be co-encapsulated with drugs in the same microcapsule.
i0 A magnetic resonance contrast agent can also be encapsulated
such as various metallo-organic compounds including aqueous
soluble ferrous gluconate, Gadolinium diethylene triamine
pentaacetic acid and hydrocarbon-soluble, iron
pentacarbonyl.
15 The microcapsules of the invention have been found to
provide a surprisingly uniform distribution of diameters
(Fig. 3A and B). This uniformity is particularly important
in its medical applications. The microcapsules thus
produced can be used to deliver several drugs which can be
20 released sequentially to the target tissues. The deformable,
liquid-filled microcapsules also have advantages over solid
matrix microspheres in achieving maximum packing density in
blood vessels, thereby decreasing blood flow to target
tissues. This enhances the therapeutic effect of combined
25 drug delivery and reducing the blood supply to vascular
tumors (chemoembolization).
The methods of the invention result in more spherical,
uniform size distributions of microcapsules. When comparing
certain prior art equipment and methods for forming
30 microcapsules (Microfluidics, Inc., see Figs. 2A, B and 3A,
B), the inventors found that even the preferred formulations
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of the invention were incapable of providing such
uniformity. In certain instances, hardly any microcapsules
formed at all where mixing and vortexing were used to
distribute one phase into the next (Fig. 2A). In others,
5 poorly formed and non-spherical microcapsules resulted (Fig.
2B). In contrast to the failures of the prior art methods,
the methods of the invention were successfully used to
generate uniform, spherical microcapsules both under unit
gravity (Fig. 3A) and under microgravity conditions (Fig.
i0 3B). Such uniformity enables superior drug delivery.
Enhanced uniformity also enables better dose distribution
calculations for establishing the therapeutic dose in the
treatment of specific diseases, especially treatment of
certain types of tumors. Importantly, the methods of the
15 invention allow the formation of larger-sized,
multi-lamellar microcapsules (1-350 micron) than heretofore
possible. Such a capability allows multilamellar
microcapsules to be made specifically for inhalation and
deposition in the lungs. This uniformity allows facile
20 sieving or filtering of the microcapsule products in order
to obtain highly uniform diameter fractions.
Most liposomes have a very small hydrophobic
compartment and therefore can only carry small amounts of
hydrophobic drugs. Contrastingly, the microcapsules of the
25 invention have a relatively large hydrophobic liquid
compartment which enables delivery of more hydrophobic drug
per microcapsule. Moreover, the microcapsules of the
invention have relatively large hydrophilic and hydrophobic
compartments which permits tandem delivery of both water
30 soluble and non-water soluble drugs in the same
microcapsule.
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As previously noted, the microcapsules of the invention
may contain polysaccharides. Inclusion of such
polysaccharides is one of several aspects of the methods of
the invention that enhance the formation of the
5 microcapsules. The inclusion of injectable polysaccharides
in the formulations of the invention (similar to those
polysaccharides found in Ringer's solutions) contributes to
the driving forces that control phase separation and phase
partitioning of the entrapped drugs. The polysaccharides
i0 also provide increased shelf-life and stability of the
parenteral suspensions. Use of the osmotically neutral salt
solutions in the aqueous phase enhances micelle formation,
lateral phase separation, and increases the dispersion of
microcapsules and their stability as they are formed.
15 The methods of the invention in a preferred embodiment
utilize a non-phospholipid outer coating. The microcapsules
formed by this method are contained in a thin,
semi-permeable, outer membrane comprised of hydrophobic
(e.g.mono- or polyglycerides or waxy-polymers) or
20 hydrophilic polymers (e.g., PVA or PVP), depending on the
desired diffusion release rate of the encapsulated drug.
Thus, the coating has the advantage of allowing design of
the appropriate drug diffusion and release characteristics
while avoiding certain of the disadvantages of conventional
25 liposomes (and lipid bilayers). In particular, the coating
produced by the methods of the invention around the outer
surface of the microcapsule avoids being readily detected
and largely eliminated by the reticuloendothelial system
(RES). The outer skin protects the microcapsules against
30 shear forces encountered during manufacturing processes and
during transport within the vascular system enroute to the
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target tissues. The hydrophobic outer membrane also can be
designed to retard oxygen transport, thereby reducing
oxidative degradation of the entrapped drug and improving
the shelf-life of the parenteral suspensions. The
5 flexible/deformable outer skin on the microcapsules of the
invention results in increased packing densities within
vascular beds. This results in microcapsules superior to
solid microspheres (e.g. gelatin, albumin or starch)
commonly used for chemoembolization therapy against tumors.
i0 The formulations used to produce the microcapsules of the
invention are summarized below.
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Formulas for Primary, Secondary and Tertiary Solutions
for Microencapsulation
Group 1
primary Solutiorl
(also can contain drug)
First Solvent (75-90%)
ethyl alcohol
methyl alcohol
isopropyl alcohol
Organic Co-solvent 0-20%
C4-C s alcohols
tetrahydrofuran (TI-IF)
dioxane
acetonitrile
dimethyl formamide (DMF)
dimethyl sulfoxide (DMSO)
Polymers
(1-5%) (monoglycerated)
glycerol monostearate
glycerol monooleate
glycerol monolaurate
(polyglycerides)
glycerol dioleate
glycerol distearate
(sterols)
cholesterol
plant sterols -
stigmasterol
phytosterol
campesterol
(phospholipids)
lecithins
e.g.,phosphatydl choline
(Centrolex-F')
Secondary
Solutiotl
Second Solvent water
(70-98%)
Polymers
(1-10%)
polyethylene
glycol
PEG - 1000-8000
(polysaccharides)
Dextran 4000-
20000
(range 10000-
100000))
others
polyvinyl-
pyrrolidone
polyvinyl alcohols
Surfactants
(ionic and non-ionic)
(1-4%)
sorbitan
monooleate plus
ethylene oxides
Dextran
PEG
C12-C_q0fatty acid
quaternary NH 4
salt
Tertiar_
Solution
(also can contain dissolved
drug)
Oils (up to 100%)
IPO
heavy mineral oil
olive oil
same as in
primary soln.
paraff'ms
(c2o-Gs)
Alternative
Aqueous solutions containing
immunoglobulins
albumin
gelatin
hydrocolloids
plant sterols
phospholipids
polysaccharides
- starches
- cyclodextrins
Polymers
Surfactants (1-4%)
(ionic and non-ionic)
long chain
amphoteric salts
celluloses
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(alsocan containdrug)
Water (I-5%) water
Oil.___s
(unsamra_d or saturated)
(1-10%)
iodlnated poppy seed oil (IPO)
mineral oil
cotton seed oil
olive oil
safflower oil
canola oil
peanut oil
sesame oil
eom oil
Dissolved Drugs
(1% to saturation)
Scconda,ry
Solution
_mers
(tq0_)
0aydroeolloids)
gelatin
gum tragacanth
carragcenans
karaya gum
guar gum
alginates
(celluloses)
celluloses
(CMC, WEC,
HPC)
Salts
0-3_)
NaCI
KCI, CaCI 2,
quaternary NH 4
salts,
cetyl
trimethylammonium
bromide, 2M2A-
AMP,
PPD
Dissolved Drugs
(1% to saturation)
therapeutic of choice
Tertiar,/
Solutiorl
(also can contain dissolved
drug)
Additional Polymers
Same as secondary solution
Dissolved Drugs,
(1% to saturation)
soluble therapeutic
-36-
MSC-22489-I
Group 2
Express Mail
Table 1 (cont'd)
Certificate #GB039540919US
Patent Application
Primary Solutio.
(also can contain drug) .
Aqueous First Solvent _,ater
(70-90%)
Co-solvents (0-20 %)
C3-C a alcohols
tetrahydrofuran (FHF)
dioxane
acetonitrile
dimethylformamide (DMF)
dimethyl sulfoxide (DMSO)
Polymers hydrophilic
(water soluble)
polyvinylpyrrolidone (PVP)
polyvinyl alcohols (PVA)
hydrocolloids
gelatin
gum tragacanth
carrageenans
karaya gum
guar gum
a__nates
celluloses CMC, CPC
phospholipids
lecithias
phosphatydl choline
Centrolex F
polysaccharides
corn starch
cyclodextrins
Oils (unsaturated or saturated)
1-10%
iodinated poppy seed oil
ripe)
mineral oil
cotton seed oil
olive oil
safflower oil
canola oil
peanut oil
semi me oil
corn oil
Dissolved Druzs
1% to saturation
Secondary Solutioq
Same as Group 1
.Co-Solvents
Same as primary solution
(1-10%)
Same as Group 1
Surfactants (1-20%)
(ionic and non-ionic)
Same as Group 1
Additional Polymers 1-10%
Salts (1-3 %)
Same as Group 1
Dismlved Druzs
1% to saturation
Tertiary Solutioq
(also can containdissolved
drug)
Oil__.._s(up to 100%)
Same as Group I
Alternatives
Aqueous solutions
Same as Group 1
Polymers
Same as Secondary Solution
Surfactants
Same as Secondary Solution
Dissolved Drugs
1% to saturation
-37-
MSC-22489-I
Express Mail Certificate #GB039540919US
Patent Application
The formulations of the invention, in preferred
embodiments, are _ess toxic than conventional liposomes and
other microcapsules by avoiding use of certain phospholipids
and long chain amines (eg. sterylamine) contained in
5 conventional microspheres which can produce toxic side
effects.
Where the microcapsules of the invention comprise a
pharmaceutical composition, certain medically related
advantages may be obtained. Thus, due to the uniformity and
I0 ease with which the methods of the invention allow formation
of multilamellar microcapsules, co-encapsulation of multiple
drugs is made possible. Thus, for instance, as will be
described more fully below, co-encapsulation of drugs and
radiocontrast medium in the same microcapsules is made
15 possible by the methods of the invention. Such co-
encapsulation allows radiological monitoring of the tissue
distribution during intravascular delivery. Additionally,
incorporation of fluorescent-labels for entrapped drugs
enables accurate measure of the drug compartment volumes
20 (using fluorescent imaging techniques) and convenient
determinations of the drug loading efficiencies, particle
size distributions and measurement of shelf-life stability
of the final parenteral suspensions. In some applications
made possible by the methods and compositions of the
25 invention, the organic phase can include a tracer compound
or radiocontrast medium to provide the additional advantage
of real-time imaging of the microcapsules with computerized
tomography (CT) scanning as they are released from the
catheter enroute to the target tissue. Other examples
30 include aqueous soluble metallo-organic compounds used for
diagnostic imaging such as ferrous gluconate or Gadolinium
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diethylene triamine pentaacetic acid (Gd-DTPA) used for
nuclear magnetic resonance imaging and hydrocarbon soluble
agents such as iron pentacarbonyl which also may be used for
NMR imaging.
5 Production of multi-layered microcapsu_es via the
methods of the invention which possess alternating
hydrophobic and hydrophilic drug compartments allows for
design of multiple-therapy microcapsules. Spontaneous
formation of microcapsules with one or more large
I0 hydrophobic solvent compartments increases the potential
application for delivery of more aqueous-insoluble drug at
target sites with adequate vascular networks. By using the
microcapsules made possible by the methods of the invention,
sequential diffusion of two or more drugs out of the same
15 microcapsule may be achieved at the target tissues. The
incorporation of aqueous-soluble cyclodextrin which can act
as an internal hydrophobic drug carrier is also made
practical using the single step methods and formulations
provided in this invention. This extends the capability of
20 the invention in delivering otherwise aqueous-insoluble
drugs.
For instance, the use of multiple drugs within the same
microcapsule provides microcapsules specifically designed
for chemoembolization treatments. Multiple-drug
25 microcapsules also may be used to deliver first a
chemotherapeutic drug which kills tumor cells, and then an
immuno-adjuvant (tumor necrosis factor) or immunological
stimulant (e.g. interferon-g) that would enhance the
patient's immune response to the tumor. Multiple-drug
30 microcapsules can also be used to deliver combinations of
chemotherapeutic drugs to tumors that are located in
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privileged sites, such as brain tumors. For example, and as
described more fully in the examples to follow, simultaneous
delivery of different types of drugs in the same
microcapsule is made possible with the methods and
5 compositions of the invention, e.g. diaziquone and
cis-platinum to brain tumors via the carotid artery [Kimier
et al. 1993]. Multi-layered microcapsules may also be used
to treat deep infections that are resistant to systemic
antibiotics. In these applications, one or more antibiotics
i0 may be sequentially delivered to the site of the infection.
Multi-layered microcapsules can be designed to protect
active forms of urokinase and other thrombolytic enzymes
until they are delivered and entrapped at the local site of
a blood clot, where therapeutic doses of the enzyme may then
15 diffuse out to dissolve the unwanted embolism. The
multilamellar microcapsules can also be used to deliver
immunostimulants; cytokines such as Interferons,
Interleukins, and growth factors; antinauseants such as
metoclopramide and tetrahydrocannabinol; multiple
20 fibrinolytic enzymes such as urokinase (uPA), tissue
plasminogen activator (tPA) and streptokinase; steroids such
as hydrocortisone, dexamethasone, etc.; anti-fungals such as
nystatin and griseofulvin, anti-virals such as amatidine,
iododeoxuridine, riboviran; and multiple antibiotics such as
25 amoxicillin, ampicillin, etc.
In one embodiment, as related to the space-based
research that lead to the earth-normal embodiments of the
invention, exposure to microgravity for at least 1.0 minutes
in duration is accomplished. If the microcapsules of the
30 invention are to be used in ixg environments, as is
generally anticipated, an additional step comprising
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recovering the multi-layer microcapsules will be necessarily
accomplished at earth normal gravity. Generally, this step
will be accomplished by reentry and recovery of the orbital
device by which exposure to 0xg was accomplished. While it
5 is preferred to accomplish the recovery without exposure of
the formed microcapsules to physical extremes (pressure,
temperature, shearing, mixing, etc.), recovery of the
microcapsules of the invention have been accomplished via a
transition from microgravity to earth normal gravity at
i0 accelerations of at least 15xg without substantial loss of
integrity.
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5
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. i. Conceptual schematic showing formation of a multi-
lamellar microcapsule with an aqueous drug/oil dispersion at
its center, a hydrocarbon/oil drug #2 and/or radiocontrast
medium (e.g. IPO) as a next layer, aqueous layer/drug (cis-
platinum) as a next layer, and a polymer outer skin.
i0
Fig. 2. Photomicrographs of prior art method (vigorous
mixing) to make microcapsules. Fig. 2A shows a typical
result which fails to form microcapsules. Fig. 2B depicts
certain best efforts to form microcapsules using prior art
method.
15
Fig. 3. Photomicrographs depicting the distribution of
sizes of microcapsules resulting from the methods of the
invention are applied to form microcapsules. Fig. 3A shows
the typical result when the methods used under unit gravity.
Fig. 3B shows similar results when microcapsules are formed
using the microgravity methods of the invention.
2O
Fig. 4. Photomicrograph at enhanced magnification over
that of Fig. 3A and B showing details of certain
microcapsules of the invention.
25
Fig. 5. Photomicrographs of a microcapsule of the
invention which was made with a fluorescent dye. Fig. 5A
shows a single microcapsule without using fluorescence
microscopy. Fig. 5B shows the same microcapsule as
photographed using fluorescence microscopy.
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Fig. 6. Microcapsules With crystalline structures in their
internal layers om shells. Fig. 6A shows a microcapsule
with a single cubic crystal of Cis-Platinum trapped within.
Fig. 6B shows a microcapsule with numerous crystals of Cis-
5 Platinum formed within.
Fig. 7. Microcapsules which have been treated to contain a
radio-contrast oil (iodinated poppy seed oil) and crystals
of Cis-Platinum.
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DESCRIPTION OF PREFERRED EMBODIMENTS
A series of more than 38 separate experiments on four
space flights has led to the development of this invention.
These experiments along with their ground-based counterparts
are described below for the purpose of pointing out the
invention specifically and providing details useful in
carrying out the invention. These specific examples,
however, do not limit the scope of the claimed invention.
Referring first to the figures, Fig. 1 is a conceptual
i0 schematic showing formation of a multi-lamellar microcapsule
i0 with an aqueous drug/oil dispersion 12 at its center 14,
a hydrocarbon/oil drug#2 and/or radiocontrast medium (e.g.
IPO) 16 as a next layer 18, an aqueous layer/drug (cis-
platinum) 20 as a next layer 22, and a polymer outer skin
15 24. A first hydrocarbon phase 26 and a second aqueous phase
28, initially separated, are allowed to form an interface 21
with minimal mixing and low shear. If only diffusion-driven
convection is allowed to occur at interface 21 thereafter,
microcapsules of the invention form representative of that
20 depicted i0.
Fig. 2 is a pair of photomicrographs of the resulting
mixture when a prior art method (utilizing vigorous mixing)
is used with the preferred formulations of the invention to
attempt to make microcapsules at earth normal gravity. Fig.
25 2A shows a typical result which fails to form microcapsules
of any kind. Fig. 2B depicts certain best efforts to form
microcapsules using this method. In Fig. 2B, in can be seen
that certain poorly formed microcapsules 30 have formed.
Typically, these microcapsules will demonstrate considerable
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lack of sphericity 32, coalescence 34, and non-uniformity
36.
In Fig. 3, a pair of photomicrographs of the resulting
mixture of when the methods of the invention are applied to
5 form microcapsules. Fig. 3A shows the typical result when
the methods of the invention are used to form microcapsules
under unit gravity, at temperatures below ambient. Numerous
microcapsules wherein the first phase is an organic phase
formed, including certain ones of considerable diameter 40
i0 as well as those of fairly small diameter 42. Fig. 3B shows
similar results when microcapsules are formed using the
microgravity methods of the invention using a first aqueous
phase. Again, numerous microcapsules, including certain
ones of considerable diameter 44 as well as those of fairly
15 small diameter 46 form. It is clear from such
photomicrographs, that uniformity and sphericity is a common
characteristic of the microcapsules of the invention,
regardless of the gravity environment.
Fig. 4 is a photomicrograph at enhanced magnification
20 over that of Fig. 3A and B showing details of certain
microcapsules of the invention when practiced at unit
gravity. A single large microcapsule 50 and several smaller
ones 52 are shown. Nested inside microcapsule 50 can be
seen several oil solvent spheroids (olive oil) 51 each of
25 which is surrounded by the inner aqueous layer 54. A outer
polymeric coating 56 can be seen on microcapsules 50 and 52.
It is also possible to detect 3-4 spherical shells 58 nested
within one another on certain of the smaller microcapsules
60.
30 Fig. 5 is a photomicrograph of a microcapsule formed
under microgravity of the invention which was made with a
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fluorescent dye in order to demonstrate the ability of the
microcapsules of the invention to segregate a drug into a
distinct layer. Fig. 5A shows a single microcapsule 70 in
focus without using fluorescence microscopy comprising a
5 outermost polymeric coating 72, an internal hydrocarbon
solvent phase 74, a second polymeric membrane 76, aqueous
spheroids 78 contained within the hydrocarbon inner layer
74, and an aqueous shell layer 80. Fig. 5B shows the result
when the same microcapsule was photographed using a light
i0 source and optics to enable visualization of the fluorescent
dye location, the internal spheroids 78 and aqueous shell or
layer 80 are seen to fluoresce to indicate the location of
the dye 82 therein.
Fig. 6 depicts the capacity of the methods of the
15 invention to create spherical microcapsules of uniform and
substantial volumes which are capable of forming crystalline
structures in their internal layers or shells. Fig. 6A
shows a microcapsule 90 with a single cubic crystal of Cis-
platinum 92 trapped within. Fig. 6B shows a microcapsule 94
20 with numerous crystals of Cis-Platinum 96 formed within.
Fig. 7 shows a collection of microcapsules ii0 of the
invention which have been treated to contain a radio-
contrast oil (iodinated poppy seed oil) i00 and crystals of
Cis-Platinum 102 contained in microcapsules 104 with uniform
25 spherical shells 106 and an outer polymeric coating 108.
3O
Ex_unDl@ I: MICROGRAVITY EXPERIMENTS SUMMARY
The basic formulations and simplified liquid-liquid,
dispersion methods were developed in 1988 and 1989. The
conceptual approach is shown in Fig. i. Fig. 1 is a
schematic showing formation of a multi-lamellar microcapsule
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with an aqueous drug/oil dispersion at its center, a
hydrocarbon/oil drug#2 and/or radiocontrast medium (e.g.
IPO) as a next layer, an aqueous layer/drug (e.g., cis-
platinum) as a next layer, and a polymeric outer coating or
5 skin. Microencapsulation-related experiments designed to
overcome the limitations of the first methods were conducted
on six space missions beginning in April 1989 with the
Consort-I sounding rocket using the Materials Dispersion
Apparatus (MDA) mini-lab developed by Instrumentation
i0 Technology Associates, Inc. The sounding rocket flights
produced only 6.5 minutes of microgravity conditions, but
this was adequate to form the unique microcapsules in a
single step. Experiments on the Space Shuttle permitted i0
minute dispersion times followed by curing of the outer
15 polyglyceride skin for eight days under microgravity
conditions. A summary of these experiments is shown in Table
2. New formulations were tested on Shuttle STS-52, using
only aqueous-soluble drugs, polymers and surfactants, and on
STS-56 using alcohols as co-surfactants. The specific
20 experiments and results are described in detail in the
examples to follow.
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Table 2. MED Flight Experiments Suaimary
I
MISSION DATE EXPERIMENTS I MATERIALS
RESULTS
Consort-1 4/89 urokinase & antibodies
Consort-I 3/90
Consort-4 II/91
Consort-5
STS-52
STS-56
9/92
10/92
4/93
' Fluorescent labels included
protein diffusion
I
diffusion kinetics
microencap-
sulationof drugs"b
microencap-
sulation of drugs "b
microencap-
sulation of drugs
(aqueous polymers
only) "b
microencap-
sulation of drugs
(alcohol co-surfact-
ants) "b
urokinase &
myoglobin
Cis-Platinum,
amoxicillin, urokinase
& Strept-avidin
Cis-platinum,
amoxicillin &
urokinase
Cis-platinum,
amoxicillin &
urokinase
Cis-platinum,
amoxicillin &
urokinase
° Fluorescent beads included
diffusion rates
established
kinetics verified
multi-lamellar microspheres wl
alternating hydrophilic &
hydrophobic layers
multi-lamellar microspheres w/
alternating hydrophilic &
hydrophobie layers
multi-lamellar microspheres,
crystals within microcapsules
multi-lamellar microspheres,
crystals within microcapsules
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Ex 1 II: GRAVITY-DEPENDENT RESTRICTIONS RECOGNIZED
Gravity-dependent restrictions in the basic
liquid-liquid spontaneous microencapsulation process led to
the design of several microgravity experiments to explore
5 the utility of this process when density-driven phenomena
were eliminated. In particular, density-driven, gravity-
dependent restrictions of the liquid-liquid
microencapsulation process were: early phase separation
producing fragile microcapsules; interfacial dynamic flow
i0 causing coalescence of microcapsules. Failure of ground-
based experiments to derive uniform microcapsules lead to a
desire to attempt microcapsule formation in space.
The microgravity flight experiments led to the
development of a new liquid-liquid microencapsulation
15 process that involves use of surfactants and co-surfactants
in the aqueous phase and co-surfactant alcohols in the
organic phase, which also contained, in one embodiment, high
molecular weight polymers that formed a tough outer "skin"
on the final microcapsules. In microgravity, a single step
20 dispersion produced unique multi-lamellar microcapsules
containing various aqueous drugs co-encapsulated with
iodinated poppy seed oil (a radiocontrast medium with asp.
gravity =1.35). Subsequent ground control experiments also
produced some of these unique microcapsules and illustrated
25 that the 1 x g process could be improved to yield useable
microcapsules by using different formulations. In
particular, it became clear that the outer coatings
substantially improved the ruggedness of the microcapsules
formed.
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Example III: SOUNDING ROCKET EXPERIMENTS
Initial expe<iments on Consort-i and -3 were used to
determine the effective mixing and diffusion kinetics in the
MDAs (see below for apparatus description). This showed
5 that sufficient volume was mixed at the interface via
diffusion to allow formation of microcapsules. These
experiments also provided the diffusion constants for each
of the components of the liquid phases.
The first successful microencapsulation of drugs in
i0 microgravity was conducted on the Consort-4 mission in
November 1991. The microcapsules were recovered and
analyzed by microscopic image analysis. Mono-dispersed
fluorescent beads were included as internal size standards
and fluorescent labels were used to determine the
15 distribution of drug in the various fluid compartments.
Additional experiments, conducted on Consort-5 in September
1992, confirmed the capabilities of the new method for
forming multi-lamellar microcapsules with alternating layers
of hydrophilic and hydrophobic drugs.
20 Microcapsules formed in 38 microgravity
mini-experiments used liquid-liquid dispersion of aqueous
drug solutions, surfactant and polyethylene glycol dispersed
in alcoholic co-surfactant solutions containing soluble
polyglycerides.
25 Microcapsules of both oil/water and polymer/water/oil
were recovered from the Consort flights. These experiments
produced multi-lamellar liquid microcapsules (concentric
spheres within spheres) comprised of three or more,
alternating immiscible layers. Image analysis of the
30 microcapsules was made possible by co-encapsulation of
standard size fluorescent beads. Microcapsules were formed
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in the ranges of 1-15 microns, 40-50 microns, 110-130
microns and 160-230 microns in diameters. This was a
substantial improvement over the prior art approaches which
had initially been attempted by the inventors to derive
5 microcapsules only in the i0 micron and less range. The
size distribution covered a range of from about as low as 5
microns in diameter up to about 300 microns in diameter and
greater. The average size of the microcapsules formed in
these experiments was about 150 microns, greatly in excess
i0 of the average i0 micron or less diameters obtained with
prior art approaches.
The ruggedness of the microcapsules formed under these
conditions allowed for size segregation by sieving. Digital
analysis (National Institutes of Health image analysis
15 program) of phase contrast and fluorescent images taken with
a fluorescent microscope also confirmed that the
aqueous-soluble drugs were routinely encapsulated within the
inner aqueous core and the outermost aqueous shell of the
microcapsules.
20 This typical distribution is illustrated in Fig. 5,
which is a composite of a transmitted light photomicrograph
and a fluorescent photomicrograph (lower right) of the same
multi-lamellar microcapsule. The polyglyceride skin is
clearly shown in th_ normal-light photomicrograph (upper
25 left).
Multi-lamellar microcapsules were, also formed which
contained relatively large amounts of IPO (Guerhart
Laboratories - France, Savage Laboratories - U.S.A.) in
discrete lamella. Fig. 7 shows a microcapsule heavily
30 loaded with IPO, which often comprised up to 38% of the
total volume. Often small hemispheres of IPO were also
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found clinging to the outer surface of the large inner
(aqueous) sphere or adhered to the outer polymer skin of the
microcapsule.
Microcapsules formed by almost all of the formulations
5 survived 15+g accelerations, severe vibrations and turbulent
mixing, during the reentry of the experiment capsule, and
have remained intact for two years after recovery from
space. These multi-layered microcapsules are similar to
liquid-filled, thin-skinned, micro-balloons which are
i0 flexible enough to be manipulated on a microscope slide
without collapse.
The microcapsules formed in just 6.5 minutes of
microgravity retain their spherical shape and appear tough
enough to survive the extensive physical manipulations
15 required for sizing, final preparation and storage of
parenteral suspensions, and the fluid shear encountered
after intravascular injection.
Also formed were very unusual structures (multiple
small spheres of aqueous-soluble drug) distributed within
20 multi-lamellar o/w/o microcapsules, wherein the aqueous
spheroids are arranged in an annular ring that appears fixed
in a plane within the innermost sphere (not shown). These
ring structures remain intact when the microcapsules are
"rolled around" on the microscope slide without rupturing.
25 These structures demonstrate the ability of the methods of
the invention to form small spheroids that do not coalesce
inside the larger microcapsule. Such structures may be
advantageously used to control the specific volume to
surface area ratio in order to control the rate of diffusion
30 of a solute in such spheroids. In particular, sustained
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release of pharmaceuticals contained in such spheroids
within microcapsules may find utility.
Example IV: SPACE SHUTTLE EXPERIMENTS
Microencapsulation experiments on Consort 4 and Consort
5 5 used mixtures of aqueous-soluble drugs, IPO, C3-C8
alcohols and polyglycerides that are insoluble in aqueous
solutions. In experiments conducted on STS-52, the inventors
co-encapsulated cis-platinum (diaminodichlor-cis-platinum;
Bristol Laboratories) with IPO by forming microcapsules from
I0 water-soluble polymers using special formulations of
aqueous, non-alcoholic solvents. Such formulations will
find particular utility in co-encapsulations of anti-tumor
compounds along with radiocontrast medium for tracking drugs
in the body.
15 Polyvinyl pyrolidone (PVP) and a commercial lethicin
(Centrolex-F'; a lecithins compound produced by U.S. Soya,
Inc.) were used to form multi-lamellar microcapsules at 20
oC. Fluorescent beads and fluorescent labeled were co--
encapsulated with the drugs to permit drug-distribution
20 measurements, within the various lamellae, using
fluorescence microscopy and digital image analysis at the
NASA Johnson Space Center, Houston, Texas. The final
microcapsules were suspended and recovered in either aqueous
solutions, IPO or mineral oil. The microcapsules formed by
25 these formulations were similar to those made using
alcohol-soluble polyglycerides. However, without the
hydrocarbon-soluble polyglyceride skin these microcapsules
were more fragile.
Another unique type of microcapsule was formed during
30 these experiments that was characterized by drug crystals
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formed within the inner aqueous core of the multi-lamellar
microcapsules. Fig. 6B shows an example of a microcapsule
which is packed (approximately 65% of the aqueous
compartment) with crystals of Cis-platinum, an anti-tumor
5 drug. Microcapsules containing crystals of amoxicillin were
also formed in the STS-52 experiments (not shown). These
illustrate that aqueous-soluble drugs can be encapsulated at
very high concentrations near the solubility limit of the
drug. After the microcapsules are formed the drug can become
i0 further concentrated (perhaps via the alcohol absorbing the
water from the aqueous phase in which the pharmaceutical
solute is dissolved) to form large crystals which are more
stable than the dissolved drug during prolonged storage.
Microcapsules formed from first organic solvent/polymer
15 methods appeared to be more rugged (by visual comparison
under the microscope) than those formed on STS-52 formed
from first solvent aqueous/polymer methods. The STS-56
experiments again produced multi-lamellar liquid
microcapsules (multiple concentric spheres within spheres)
20 comprised of alternating immiscible layers. Using
fluorescent 6.4 micron beads and image analysis, it was
found that the most interesting microcapsules were formed in
the range of 10-15 micron, 40-50 micron, 50-100 micron, and
160-230 micron diameters. These diameter distributions were
25 of particular interest since it is known that intraarterial
uses can accommodate 50-300 micron diameter microcapsules
while intravenous applications can only tolerate i-I0 micron
microcapsules. Thus, by segregating the microcapsules into
sized fractions (sieving), it should be possible to address
30 particular intravascular limitations.
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AS noted above, microcapsules were formed containing
crystals of cis-Platinum or amoxicillin. The crystals
apparently were formed after encapsulation. Several
microcapsules were formed that contained a single, large
5 cubic crystal of Cis-Platinum which so completely filled the
inner sphere that only about 15% of the inner volume
remained as a liquid. One encapsulated, cubic Cis-platinum
crystal was measured at 48 Z across within a 57 _ diameter
microcapsule (similar to that shown in Fig. 6A). After
i0 formation, some of the microcapsules were dispersed in an
external oil phase (either IPO or mineral oil) and allowed
to cure for eight days before return to Earth.
These microgravity experiments have shown that
formation of multi-lamellar, alternating-phase microcapsules
15 can be controlled by proper timed-sequence exposures of the
immiscible phases using special solvent formulations and
surfactants. Once formed, these microcapsules remain
spherical due to the predominant surface tension of the
internal phases and polymer/solvent phase partitioning at
20 the interfaces.
These experiments clearly demonstrated the capability
to use liquid-liquid diffusion mixing to form unique
microcapsules containing hydrophilic and hydrophobic drugs
under microgravity conditions. Thus, ground-based
25 experiments were conducted to compliment and replicate the
space experiments. These ground-based experiments were able
to replicate the size range (5-250 microns in diameter) to a
limited degree, but the average size microcapsule obtained
was about 10-40 microns in diameter. Still, this was a
30 substantial improvement over the prior art approaches which
rarely formed microcapsules over i0 microns in diameter. It
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was also observed that the ground-based experiments resulted
in less rugged microcapsules. This is likely a result of
the gravity-dependent deformations of the spherical
microcapsules as they form giving rise to areas of thinner
5 polymer deposition. Thus, the flexible microcapsules,
formed under microgravity conditions, have more uniform size
distributions than those formed in 1 x g, are more rugged,
and have a higher average diameter than ground-made
microcapsules, largely due to the absence of thermal
i0 convection, buoyancy forces, and instabilities that occur at
the immiscible interfaces.
The microgravity experiments illustrate the feasibility
of co-encapsulating aqueous-soluble drugs,
hydrocarbon-soluble drugs and oil-based contrast media
15 within a lipid-soluble, polyglyceride outer film which cures
rapidly enough to be impervious to oil or hydrocarbon
resolubilization. They also allow the formation and
harvesting of unique microcapsules which are durable enough
to be removed from the external solvent without disruption
20 or destruction of the internal phases. It is anticipated
that these microcapsules will have several advantages over
conventional liposomes that are designed for intravascular
injection.
Ex_unDl@ V: FLIGHT HARDWARE DESCRIPTION
25 The microencapsulation experiments described herein
were conducted using the Materials Dispersion Apparatus
(MDA; ITA, Inc., Exton, PA). The MDA's consist of an upper
and a lower block that contain chambers for each sample
fluid. The blocks are misaligned at launch so that the
30 chambers are not in contact with each other. Upon activation
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in microgravity, the blocks are moved to align the chambers
so that the fluids, can mix by liquid-liquid diffusion. Some
of the experiments were conducted with a single-step fluid
mixing, and some were done with a two-step fluid mixing
technique which allows diffusion of a third fluid or sample
into the mixture of the first two fluids while still in the
microgravity environment.
Examole vI: DISCUSSION AND ALTERNATIVE EMBODIMENTS
Spontaneous formation of multi-lamellar, microcapsules
i0 containing alternating layers of aqueous and hydrophobic
solvent compartments is strongly dependent on the
interfacial tension and the amount of mixing between
immiscible liquid phases. On Earth this process is limited
by gravity-dependent, density-driven separation of the
15 immiscible liquids into stratified horizontal layers. In
microgravity, this process is largely dependent on the
surface-free energies of the different liquids, but
independent of density-driven convection or buoyant phase
separation. Hydrocarbon soluble, high molecular weight
20 polymers have been included in the formulations to form
flexible, permeable "skins" or outer coatings around the
liquid microcapsules as they are created by phase
partitioning mechanisms. It is also possible to form such
polymer barriers between internal layers. The microcapsules
25 can be formed and cured without deformation by contact with
container walls.
More specifically, co-encapsulation of an
aqueous-soluble, anti-tumor drug (Cis-platinum) and a
radio-contrast medium (IPO), in microgravity, has produced a
30 unique drug delivery system that can be visualized by
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radiologic or computerized tomography scanning to insure
that the cytotoxic drug is delivered directly to the target
tumor. Multi-layered microcapsules have been developed
which can provide a new intravascular delivery system for
5 targeted tissues and sequential, sustained release of
multiple anti-tumor drugs. This method has resulted in
formation of flexible spherical microcapsules of more
uniform sizes, which can provide maximum packing densities
and maximum drug delivery to target organs or tumors.
i0 Multi-layered microcapsules can be designed to protect
active forms of urokinase and other thrombolytic enzymes
until they are delivered and entrapped at the local site of
a blood clot, where therapeutic doses of the enzyme can
diffuse out to dissolve the unwanted embolism. These
15 immiscible-liquid diffusion methods also could be used for
encapsulating certain labile drugs to make microcapsules for
special purpose drug delivery systems, especially those
designed to deliver drugs via the nasal or buccal mucosa or
via inhalation directly to the lungs. Examples include
20 protected delivery of mucolytic DNAse for sustained release
treatment of cystic fibrosis and s anti-trypsin for patients
with deficiencies in the lung epithelium.
Example VIII: REDISPERSION OF MICROCAPSULES IN AQUEOUS OR
OIL VEHICLES
25 A frequently used second step includes dispersion of
the microcapsules (after they have formed) in different
aqueous/polymer solvents or in a pure oil phase. A unique
attribute of microcapsules formed by these methods is that
they do not re-dissolve in an oily external phase, even
30 though the semi-permeable outer skin is hydrophobic. This
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produces a suspension in the liquid carriers that are
commonly used for,intravascular administration.
_KD/9_K: EXEMPLARYFIRST ORGANIC SOLVENTMICROCAPSULE
FORMULATIONS
The following formulations have been used with
particular success by the inventors in both earth normal and
microgravity methods of making microcapsules.
Fluid I - (hydrocarbon). The first solvent is a hydrocarbon
fluid (ethyl alcohol, methyl alcohol, or isopropyl alcohol)
i0 with a low or medium HLB (HLB=5-10). One or more co-
solvents are used (which also can act as co-surfactants).
Small concentrations of oil and water are added. Into this
mixture, the mono- or polyglyceride is dissolved up to 5%
w/v. An example is:
15 88% IPA
2.5% m-Hexanol
2.5% n-Heptanol
5% IPO
2% H20
20 5% GMS
25
Fluid 2 (aqueous). The second solvent is water plus
surfactants (ex. polyethoxylated sorbitan esters;
polyethylene glycol). A polysaccharide (Dextran) and normal
saline (0.9%) are added which helps achieve the desired
critical micelle concentration. A pharmaceutical soluble in
water is added. An example is:
1% PEG 4000
5% Dextran-40 (MW=40,000)
0.9% Sodium chloride
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2% Sorbitan Monooleate/20 moles Ethylene oxide
Water (Dp to 100% volume)
dissolved drug at specified concentration
(according to required dose and release rate)
5 Fluid 3 (oil). An oil, immiscible with the first two fluids
in which the microcapsule's "outer skin" is insoluble so
that the suspended microcapsules can be delivered by
injection when non-aqueous administration is required.
Submersion of microcapsules in the oil also can aid the
i0 curing or polymerization of the "outer skin." A preferred
example of the oil vehicle is iodinated poppy seed oil which
also serves as a radiocontrast medium.
Alternate compositions for Fluid 1
M_n solvent - ethyl alcohol
15 Co-solvents - (co-surfactants) are normal alcohols - C4 to
C8
high dielectric constant solvents -
tetrahydrofuran
dioxane
20 acetonitrile
dimethylformamide
dimethylacetamide
dimethylsulfoxide
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5
9/i dense radiocontrast liquids s.a. iodinated
unsaturated oils
e.g. poppy seed oil, cotton seed oil, safflower
oil, olive oil, canola oil, peanut oil, sesame
oil, corn oil.
also saturated oils can be used, s.a. heavy
mineral oil, liquid petrolatum
pQlvmers - used to form the "outer skin" on the
microcapsules monoglycerides - esp. glycerol
i0 esters ranging from C12 - C22,
e.g. monostearate, distearates, monooleates,
monolaurates and olive oil
polyglycerides - cholesterol, waxy plant sterols
(stigmasterol, phytosterol, campesterol)
15 phospholipids - lecithins (phosphatydl choline)
and/or combinations with mono/polyglycerides
20
Alternate concentrations:
Fluid i: Main solvent
Co-solvents
Oil
Polymer
Water
75-95%
1-10%
1-10%
1-5%
1-20%
25
Al_rn_Z@ composition for Fluid 2
PEG 200-10000
Dextran-40 (MW = 40,000-70,000)
0.9% Sodium chloride
Sorbitan Monolaurate/20 moles Ethylene oxide
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balance is water
Drug dissolved at saturated or specified
concentration
(according to required dose and release rate)
5 Alternate concentrations:
PEG 1-5%
Dextran (MW=40,000-70,000) 5-10%
Sodium chloride 0.9%
Sorbitan Monolaurate/20ETO 1-5%
I0 Water (balance of volume)
Drug concentration saturated or specified
15
Alternate composition for Fluid 3 (Oils)
Dense radiocontrast liquids s.a. iodinated unsaturated
oils e.g. poppy seed oil, cotton seed oil, safflower oil,
olive oil, canola oil, peanut oil, sesame oil, corn oil.
Also saturated oils can be used, s.a. heavy mineral oil
Alternate concentrations: 100% oil or a mixture is used as
a carrier vehicle for the suspended microcapsules
Ex_unple X: EXEMPLARY FIRST AQUEOUS SOLVENT MICROCAPSULE
20 FORMULATIONS
ALTERNATE METHOD - Hydrophilic Outer Skin
Fluid 1 - (aqueous); the main solvent is a water, one or
more co-solvents (which also can act as co-surfactants), and
a lecithins is dissolved up to 5% w/v to form the outer skin
25 on the microcapsules.
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An example is: 3% polyvinyl alcohol dissolved
in a mixture of
20% isopropyl alcohol and
80% water
Fluid 2 (aqueous); the main solvent is water plus
surfactants (ex. polyethoxylated sorbitan esters;
polyethylene glycol) and plus a polysaccharide (Dextran) and
normal saline (0.9%) which helps achieve the desired
critical micelle concentration.
I0 An example is:
15
1% PEG 4000
5% Dextran-70 (MW=-70,000)
0.9% Sodium chloride
2% Sorbitan Monooleate/20 moles
Ethylene oxide
Water (up to 100% volume)
dissolved drug at saturated or
specified concentration
(according to required dose
and release rate)
20 Fluid 3 (aqueous) - a PEG and PVP solution which can aid the
curing or polymerization of the "outer skin."
25
1% Polyvinyl pyrollidone
4% PEG 4000
5% Dextran-70 (MW=-70,000)
balance is 0.9% Sodium chloride
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The present invention has been described in terms of
20 particular embodiments found or proposed to comprise
preferred modes for the practice of the invention. It will
be appreciated by those of skill in the art that, in light
of the present disclosure, numerous modifications and
changes can be made in the particular embodiments
25 exemplified without departing from the intended scope of the
invention. For example, one alternate embodiment includes
use of aqueous-soluble cyclodextrin (in the hydrophilic
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phase) which has hydrophobic center that can itself entrap
hydrophobic drugs thereby acting as a carrier for
hydrophobic drugs within the aqueous phase. Another
alternate embodiment allows after microcapsules are formed,
5 for ancillary polymeric outer coats to be applied by
conventional methods (electrostatic coating, aerosolization
and drying, etc.). This is made possible by designing the
precise chemical makeup of the initial polymeric outer skin
such that it will be compatible with both drug diffusion and
i0 the ancillary coating to be applied. When surfactants are
used to facilitate adhesion of the third solution or
ancillary coating the HLB must be selected to be compatible
with the HLB of the existing outer coating which has already
been formed, such that the solution containing the ancillary
15 coating will wet the surface of the existing outer coating,
to enable deposition of the ancillary coating. This is in
contrast to conventional liposomes whose outer membrane
composition is a variable, depending on the phase separation
of the phospholipids and cholesterol adduct when each
20 liposome forms. Another alternative embodiment incorporates
an energy absorbing medium ( e.g. photoactivator) which can
absorb electromagnetic, ultraviolet, infrared, ultrasonic,
radiofrequency and microwave radiation and thereby cause
activation of a short-lived drug component just prior to
25 administration or after the microcapsules have reached the
target site. Another embodiment incorporates magnetic
particles and magnetic fields or free-fluid electrophoretic
mechanisms, etc. to facilitate dispersion or transport of
one phase across the immiscible interface into the other
30 phase. This has been demonstrated as a single pass, uni-
directional form of mixing that is best exploited in
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microgravity. Another embodiment includes attachment of
certain (hydrophobic) antibodies to the polymeric skin which
gives the microcapsules site specificity by being able to
bind to target cells (e.g. tumor) while entrapped drugs
5 diffuse out to provide maximum doses to those cells with
that antigenic site. Another embodiment makes use of
polyethylene glycol (PEG) complexed to peptide or protein
drugs and a customized polymeric outer skin which permits
the drug-PEG complex to diffuse out of the microcapsule as
I0 an intact entity. This permits the drug to resist antibody
attachment and remain in the blood stream longer as found in
the Pegnology m type of drug complexes developed by Enzon,
Inc. The improvement being delivery of this complex in
the tailored microcapsules and controlled release of the
15 complex through the specially designed polymeric outer skin.
All such modifications are intended to be included within
the scope of the appended claims.
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WHAT IS CLAIMED IS:
i ,
J
A method of making a multi-layered microcapsule,
comprising:
formulating a first phase comprising a first
solvent, a first polymer soluble in said first phase,
oil, and water;
formulating a second phase immiscible with said
first phase, said second phase comprising a second
solvent, a second polymer soluble in said second phase,
a surface active agent, and a salt;
said surface active agent having a
hydrophilic/lipophilic balance value greater than that
of said first polymer;
said second polymer having a
hydrophilic/lipophilic balance value lower than that of
said surface active agent;
creating an interface between said first and
second phases in a manner that limits fluid shear; and,
maintaining adsorptive surface characteristics at
said interface.
,
,
The method of claim 1 wherein said first solvent is
organic.
The method of claim 2 wherein said organic solvent is
selected from the group of organic solvents consisting
of methyl alcohol, ethyl alcohol, and isopropyl
alcohol.
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The method of claim 1 wherein said first polymer is
selected frog the group of polymers consisting of
glycerol monosterate, glycerol monooleate, glycerol
monolaurate, glycerol dioleate, glycerol disterate,
cholesterol, stigmasterol, phytosterol, campesterol,
and lecithins.
•
The method of claim 1 wherein said first solvent is
aqueous•
1
2
3
4
• The method of claim 5 wherein said first polymer is
selected from the group of polymers consisting of
polyvinyl pyrrolidone, polyvinyl alcohols,
hydrocolloids, and lecithins.
1
2
3
4
5
6
•
The method of claim 6 wherein said hydrocolloid is
selected from the group of hydrocolloids consisting of
gelatin, gum tragacanth, carrageenan, Karaya gum, Guar
gum, gum arabic, alginates, carboxymethyl cellulose,
hydroxypropyl cellulose, hydroxy propyl cellulose, and
carboxypropyl cellulose.
• The method of claim i, said first phase further
comprising a co-solvent, wherein said co-solvent is
selected from the group of co-solvents consisting of
C3-C8 alcohols, tetrahydrofuran, dioxane, acetonitrile,
dimethylformamide, dimethylacetamide, and dimethyl
sulfoxide.
.
The method of claim 1 wherein said oil is selected from
the group of oils consisting of poppy seed oil, olive
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oil, peanut oil, sesame oil, cotton seed oil, soybean
oil, safflower oil, corn oil, sunflower seed oil,
canola oil, mineral oil, long chain paraffinic oil, and
liquid petrolatum.
i0. The method of claim 1 wherein said oil is an
unsaturated oil which has been halogenated.
1
2
3
4
5
II. The method of claim 1 wherein said second polymer is
selected from the group of polymers consisting of
polyethyleneglycol 1000-8000 daltons, dextran i000-
i0000 daltons, polyvinylpyrrolidone, polyvinyl
alcohols, and hydrocolloids.
i
2
3
4
5
12. The method of claim II wherein said hydrocolloid is
selected from the group of hydrocolloids consisting of
gelatin, gum tragacanth, carrageenan, Karaya gum, Guar
gum, gum arabic, alginates, carboxymethyl cellulose,
hydroxypropyl cellulose, and carboxypropyl cellulose.
13. The method of claim 1 wherein said surface active agent
has a hydrophilic/lipophilic balance value of about
i0.0 or greater.
1
2
3
4
5
6
7
14. The method of claim 13 wherein said surface active
agent is selected from the group of surface active
agents consisting of sorbitan monooleate treated with
ethylene oxide, dextran, polyethylene glycol, C12-C20
fatty acids, 2-amino-2-methyl-l-propyl aminomethyl
propanol, amphoteric salts, and quaternary ammonium
salts.
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15. The method of claim 1 wherein said salt is selected
from the gro9p of salts consisting of NaCI, KCI, CaCl 2,
MgCI2, quaternary ammonium salts, cetyl
trimethylammonium bromide, and 4-methoxy-4(3-
phosphatidyl choline)spiro(l,2-dioxetane-3-g,l-
adamantane) disodium salt.
16. The method of claim 1 wherein said first phase further
comprises a pharmaceutical composition.
1
2
3
4
5
17. The method of claim 16 wherein said pharmaceutical
composition is selected from the group of
pharmaceutical compositions consisting of cytotoxins,
proteases, cytokines, anti-nauseants, steroids, anti-
fungal agents, fibrinolytic enzymes, and antibiotics.
18. The method of claim 16 wherein said pharmaceutical
composition is in suspension.
19. The method of claim 1 wherein said second phase further
comprises a pharmaceutical composition.
1
2
3
4
5
20. The method of claim 19 wherein said pharmaceutical
composition is selected from the group of
pharmaceutical compositions consisting of cytotoxins,
proteases, cytokines, anti-nauseants, steroids, anti-
fungal agents, fibrinolytic enzymes, and antibiotics.
21. The method of claim 19 wherein said pharmaceutical
composition is in suspension.
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22. The method of claim 16 or 19 wherein said
pharmaceutic_l is at a concentration sufficient to
allow nascent crystal formation within said
microcapsule.
1
2
3
4
5
6
23. The method of claim i, wherein after said microcapsule
forms, taking additional steps comprising:
formulating a third phase comprising an oil or
C20-C38 paraffin; and,
contacting said microcapsule with said third
phase.
24. The method of claim 23, wherein said third phase
further comprises a polymer.
1 25.
2
The method of claim 23, wherein said third phase
further comprises a pharmaceutical composition.
1
2
3
4
5
6
26. The method of claim i, wherein after said microcapsule
forms, taking additional steps comprising:
formulating a third phase comprising an aqueous
solution; and,
contacting said microcapsule with said third
phase.
27. The method of claim 26, wherein said third phase
further comprises a polymer.
1 28.
2
The method of claim 26, wherein said third phase
further comprises a pharmaceutical composition.
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29.
30.
31.
32.
33.
34.
The method of claim 26, wherein said third phase
further comp<ises an adjuvant.
The method of claim 26, wherein said third phase
further comprises an activator agent.
The method of claim 29, wherein said adjuvant further
comprises an immunoglobulin, peptide, protein,
hydrocolloid or polysaccharide.
The method of claim 31, wherein said hydrocolloid is
selected from the group of such hydrocolloids
consisting of collagen, isoelectric gelatin, agar, gum
arabic, gum tragacanth, cellulose derivatives,
alginates and carrageenans.
The method of claim 26, wherein said third phase
further comprises a surface active agent compatible
with the hydrophilic/lipophilic balance value of an
outer coating of said microcapsule.
The method of claim 1 wherein one or more of said
phases further comprise fluorescent molecules selected
from the group of fluorescent molecules consisting of
fluoresceins, cyanins, naturally fluorescent molecules,
and rhodamines.
i
2
3
35. The method of claim 1 wherein said fluid shear is
limited to a force of less than about 12 dynes per
square centimeter at said interface.
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36.
37.
38.
39.
40.
41.
The method of claim 1 wherein said adsorptive surface
characteristics comprise a Helmholtz charge
distribution at said interface.
The method of claim 1 wherein said maintenance of
adsorptive surface characteristics is promoted by
carrying out the method under microgravity.
The method of claim 37 wherein said microgravity is at
least 1.0 minute in duration.
The method of claim 1 wherein said maintenance of
adsorptive surface characteristics is promoted by
carrying out the method below ambient temperature.
The method of claim 1 wherein said maintenance of
adsorptive surface characteristics is promoted by
substantially balancing the specific gravity between
said phases.
A method of making a multi-layered microcapsule,
comprising:
formulating a first phase comprising an organic
solvent selected from the group of organic solvents
consisting of methyl alcohol, ethyl alcohol and
isopropyl alcohol, a first polymer soluble in said
first phase selected from the group of polymers
consisting of glycerol monosterate, glycerol
monooleate, glycerol monolaurate, glycerol dioleate,
glycerol disterate, cholesterol, stigmasterol,
phytosterol, campesterol, and lecithins, a co-solvent
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3O
31
32
33
34
35
36
37
38
39
4O
selected from the group of co-solvents consisting of
c3-c8 alcohols, tetrahydrofuran, dioxane, acetonitrile,
dimethylformamide, dimethylacetamide, and dimethyl
sulfoxide, an oil selected from the group of oils
consisting of poppy seed oil, olive oil, peanut oil,
sesame oil, cotton seed oil, soybean oil, safflower
oil, corn oil, sunflower seed oil, canola oil, mineral
oil, long chain paraffinic oil, and liquid petrolatum,
and water;
formulating a second phase immiscible with said
first phase, said second phase comprising water, a
second polymer soluble in said second phase selected
from the group of polymers consisting of
polyethyleneglycol 1000-8000 daltons, dextran i000-
i0000 daltons, polyvinylpyrrolidone, polyvinyl
alcohols, hydrocolloids, and lecithins, a surface
active agent selected from the group consisting of
sorbitan monooleate treated with ethylene oxide,
dextran, polyethylene glycol, C12-C20 fatty acids, 2-
amino-2-methyl-l-propyl aminomethyl propanol,
quaternary ammonium salts, and a salt selected from the
group of salts consisting of NaCl, KCI, CaCI2, MgCI2,
quaternary ammonium salts, cetyl trimethylammonium
bromide, and 4-methoxy-4(3-phosphatidyl
choline)spiro(l,2-dioxetane-3-g,l-adamantane) disodium
salt;
said surface active agent having a hydrophilic/
lipophilic balance value greater than that of said
first polymer;
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said second polymer having a
hydrophilic/$ipophilic balance value lower than that of
said surface active agent;
creating an interface between said first and
second phases in a manner that substantially limits
fluid shear; and,
substantially maintaining adsorptive surface
characteristics at said interface.
42. Microcapsules produced by any of the methods of the
preceding claims.
1
2
3
43. The microcapsules of claim 42 wherein said
microcapsules are of a uniform distribution of
diameters.
44. The microcapsules of claim 43 wherein said diameter
distribution is in a range of about 1.0 to 350.0
microns.
I
2
3
45. The microcapsule of claim 42 further comprising at
least one nascent crystal of a pharmaceutical
composition.
46. The microcapsules of claim 45 wherein said crystal
occupies at least about i0 percent of the volume of
said microcapsule.
1 47. A microcapsule produced by the method of claim 41.
1 48. A multi-layered microcapsule, comprising:
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49.
50.
51.
52.
a first layer comprising a first solvent, a first
polymer soluble in said first layer, oil, and water;
a second layer immiscible with said first layer,
said second layer comprising a second solvent, a second
polymer soluble in said second layer, a surface active
agent, and a salt;
said surface active agent having a hydrophilic/
lipophilic balance value greater than that of said
first polymer; and,
said second polymer having a
hydrophilic/lipophilic balance value lower than that of
said surface active agent.
The microcapsule of claim 48 wherein said first solvent
is organic.
The microcapsule of claim 49 wherein said organic
solvent is selected from the group of organic solvents
consisting of methyl alcohol, ethyl alcohol and
isopropyl alcohol.
The microcapsule of claim 49 wherein said first polymer
is selected from the group of polymers consisting of
glycerol monosterate, glycerol monooleate, glycerol
monolaurate, glycerol dioleate, glycerol disterate,
cholesterol, stigmasterol, phytosterol, campesterol,
and lecithins.
The microcapsule of claim 48 wherein said first solvent
is aqueous.
-77-
NOT FOR DISSEMtNAItON ,,,LoL
" _' '_"_"AR_ IN THE PEI',PDIN[;
, L. r',_ _,J
Ai;PLIC/'JION A_'ID [_AY NI][ I_F_
ALLOWED
MSC-22489-I
Express Mail Certificate #GB039540919US
Patent Application
1
2
3
4
53. The microcapsule of claim 52 wherein said first polymer
is selected from the group of polymers consisting of
polyvinyl pyrrolidone, polyvinyl alcohols,
hydrocolloids, and lecithins.
1
2
3
4
5
6
54. The microcapsule of claim 53 wherein said hydrocolloid
is selected from the group of hydrocolloids consisting
of gelatin, gum tragacanth, carrageenan, Karaya gum,
Guar gum, gum arabic, alginates, carboxymethyl
cellulose, hydroxypropyl cellulose, and carboxypropyl
cellulose.
1
2
3
4
5
6
55. The microcapsule of claim 48, said first layer further
comprising a co-solvent, wherein said co-solvent is
selected from the group of co-solvents consisting of
C3-C 8 alcohols, tetrahydrofuran, dioxane, acetonitrile,
dimethylformamide, dimethylacetamide, and dimethyl
sulfoxide.
1
2
3
4
5
6
56. The microcapsule of claim 48 wherein said oil is
selected from the group of oils consisting of poppy
seed oil, olive oil, peanut oil, sesame oil, cotton
seed oil, soybean oil, safflower oil, corn oil,
sunflower seed oil, canola oil, mineral oil, long chain
paraffinic oil, and liquid petrolatum.
57. The microcapsule of claim 48 wherein said oil is an
unsaturated oil which has been halogenated.
58. The microcapsule of claim 48 wherein said second
polymer is selected from the group of polymers
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consisting of polyethyleneglycol 1000-8000 daltons,
dextran i000<i0000 daltons, polyvinylpyrrolidone,
polyvinyl alcohols, gelatin, gum tragacanth,
carrageenan, Karaya gum, Guar gum, gum arabic,
alginates, carboxymethyl cellulose, hydroxypropyl
cellulose, carboxypropyl cellulose, and lecithins.
i
2
3
59. The microcapsule of claim 48 wherein said surface
active agent has a hydrophilic/lipophilic balance value
of about i0.0 or greater.
1
2
3
4
5
6
7
60. The microcapsule of claim 59 wherein said nonionic
surface active agent is selected from the group of
nonionic surface active agents consisting of sorbitan
monooleate treated with ethylene oxide, dextran,
polyethylene glycol, C12-C2o fatty acids, 2-amino-2-
methyl-l-propyl aminomethyl propanol, amphoteric salts,
and quaternary ammonium salts.
1
2
3
4
5
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61. The microcapsule of claim 48 wherein said salt is
selected from the group of salts consisting of NaCl,
KCl, CaCI 2, MgCI2, quaternary ammonium salts, cetyl
trimethylammonium bromide, and 4-methoxy-4(3-
phosphatidyl choline)spiro(l,2-dioxetane-3-g,l-
adamantane) disodium salt.
62. The method of claim 48 wherein said first layer further
comprises a pharmaceutical composition.
1
2
63. The microcapsule of claim 62 wherein said
pharmaceutical composition is selected from the group
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of pharmaceutical Compositions consisting of
cytotoxins, proteases, cytokines, anti-nauseants,
steroids, anti-fungal agents, fibrinolytic enzymes, and
antibiotics.
1
2
64.
65.
The microcapsule of claim 62 wherein said
pharmaceutical composition is in suspension.
The microcapsule of claim 48 wherein said second layer
further comprises a pharmaceutical composition.
1
2
3
4
5
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66. The microcapsule of claim 65 wherein said
pharmaceutical composition is selected from the group
of pharmaceutical compositions consisting of
cytotoxins, proteases, cytokines, anti-nauseants,
steroids, anti-fungal agents, fibrinolytic enzymes, and
antibiotics.
1
2
3
4
67.
68.
The microcapsule of claim 65 wherein said
pharmaceutical composition is in suspension.
The microcapsule of claim 62 or 65 wherein said
pharmaceutical is at a concentration sufficient to
allow nascent crystal formation within said
microcapsule.
1
2
69. The microcapsule of claim 48 comprising a third layer,
said third layer comprising an oil or paraffin.
70. The microcapsule of claim 69, wherein said third layer
further comprises a polymer.
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The microcapsule of claim 69, wherein said third layer
further comprises a pharmaceutical composition.
1
2
72 The microcapsule of claim 69, wherein said third layer
further comprises a surface active agent.
73 The microcapsule of claim 48 comprising a third layer,
said third layer comprising an aqueous solution.
1 74
2
The microcapsule of claim 73, wherein said third layer
further comprises a polymer.
1 75
2
The microcapsule of claim 73, wherein said third layer
further comprises a pharmaceutical composition.
1
2
76 The microcapsule of claim 73, wherein said third layer
further comprises an adjuvant.
77 The microcapsule of claim 76, wherein said adjuvant
further comprises an immunoglobulin, peptide, protein,
hydrocolloid or polysaccharide.
78. The microcapsule of claim 77, wherein said peptide or
said protein selectively adheres to a target cell,
tissue or tumor.
1
2
3
4
5
79. The microcapsule of claim 77, wherein said hydrocolloid
is selected from the group of such hydrocolloids
consisting of collagen, isoelectric gelatin, agar, gum
arabic, gum tragacanth, cellulose derivatives and
carrageenans.
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80. The microcapsule of claim 73, wherein said third layer
further compTises a surface active agent.
1
2
3
4
5
81. The microcapsule of claim 48 wherein one or more of
said layers further comprise fluorescent molecules
selected from the group of fluorescent molecules
consisting of fluoresceins, cyanins, naturally
fluorescent molecules, and rhodamines.
1 82. The microcapsule of claim 48 formed under microgravity.
83. The microcapsule of claim 82 wherein said microgravity
is at least 1.0 minutes in duration.
84. The microcapsule of claim 48 formed below ambient
temperature.
85. The microcapsule of claim 48 comprising layers at least
initially substantially balanced as to specific gravity
between said layers.
1 86.
2
3
4
5
6
7
8
9
i0
A multi-layered microcapsule, comprising:
a first layer comprising an organic solvent
selected from the group of organic solvents consisting
of methyl alcohol, ethyl alcohol and isopropyl alcohol,
a first polymer soluble in said first phase selected
from the group of polymers consisting of glycerol
monosterate, glycerol monooleate, glycerol monolaurate,
glycerol dioleate, glycerol disterate, cholesterol,
stigmasterol, phytosterol, campesterol, and lecithins,
a co-solvent selected from the group of co-solvents
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consisting of C3-C8 alcohols, tetrahydrofuran, dioxane,
acetonitrile_ dimethylformamide, dimethylacetamide, and
dimethyl sulfoxide, oil selected from the group of oils
consisting of poppy seed oil, olive oil, peanut oil,
sesame oil, cotton seed oil, soybean oil, safflower
oil, corn oil, sunflower seed oil, canola oil, mineral
oil, a long chain paraffinic oil, and liquid
petrolatum, and water;
a second layer immiscible with said first layer,
said second layer comprising water, a second polymer
soluble in said second phase selected from the group of
polymers consisting of polyethyleneglycol 1000-8000
daltons, dextran i000-i0000 daltons,
polyvinylpyrrolidone, polyvinyl alcohols, gelatin, gum
tragacanth, carrageenan, Karaya gum, Guar gum, gum
arabic, alginates, carboxymethyl cellulose,
hydroxypropyl cellulose, carboxypropyl cellulose, and
lecithins, a surface active agent sorbitan monooleate
treated with ethylene oxide, dextran, polyethylene
glycol, C12-C20 fatty acids, 2-amino-2-methyl-l-propyl
aminomethyl propanol, amphoteric salts, and quaternary
ammonium salts, and a salt selected from the group of
salts consisting of NaCI, KCI, CaCI 2, MgCI2, quaternary
ammonium salts, cetyl trimethylammonium bromide, and 4-
methoxy-4(3-phosphatidyl choline)spiro(l,2-dioxetane-3-
g,l-adamantane) disodium salt;
said surface active agent having a
hydrophilic/lipophilic balance value greater than that
of said first polymer; and,
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said second polymer having a
hydrophilic/lipophilic balance value lower than that of
said surface active agent.
The microcapsule of claim 62 further comprising at
least two different pharmaceuticals, a first
pharmaceutical in said first phase and a second
pharmaceutical in said second phase.
The microcapsule of claim 48 further comprising a
radiopaque contrast agent.
The microcapsule of claim 48 further comprising a
magnetic resonance contrast agent.
The microcapsule of claim 89 wherein said contrast
agent is selected from the group of metallo-organic
compounds consisting of ferrous gluconate, Gadolinium
diethylenetriamine pentaacetic acid, and iron
pentacarbonyl.
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ABSTRACT
Methods of forming multi-lamellar microcapsules having
alternating layers of hydrophilic and hydrophobic immiscible
liquid phases have been developed using different
5 polymer/solvent systems. The methods use liquid-liquid
diffusion and simultaneous lateral phase separation,
controlled by proper timed-sequence exposures of immiscible
phases and low shear mixing, to form narrow size
distributions of spherical, multilamellar microcapsules.
i0 The use of special formulations of solubilized drugs,
surfactants, and polymeric co-surfactants in aqueous
vehicles which are dispersed in hydrocarbon solvents
containing small quantities of oil, low molecular weight
co-surfactants and glycerides that are aqueous insoluble
15 enables the formation of unique microcapsules which can
carry large amounts of pharmaceuticals in both aqueous and
non-aqueous solvent compartments. The liquid microcapsules
are quickly formed in a single step and can include a
polymeric outer "skin" which protects the microcapsules
20 during physical manipulation or exposure to high shear
forces. Water-in-oil and oil-in-water microcapsules have
been formed both in 1 x g and in microgravity, which contain
several types of drugs co-encapsulated within different
fluid compartments inside the same microcapsule. Large,
25 spherical multi-lamellar microcapsules have been formed
including a cytotoxic drug co-encapsulated with a
radiocontrast medium which has advantages for
chemoembolization of vascular tumors. In certain cases,
crystals of the drug form inside the microcapsules providing
30 zero-order and first order, sustained drug release kinetics.
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